Master Alliance Provisions Guide (MAPGuide)

Search Results For:

  • No search criteria provided
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Alnylam Pharmaceuticals - University of British Columbia- AlCana Technology, Sponsored Research Agreement
2009
Academic institution
Industry
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
PATH - Aridis, Rotavirus Vaccine Development Agreement
2007
Industry
Product development partnership
Vaccine
Early clinical (through Phase 2)
UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Vaccine
Commercialization
AUTM Model Inter-Institutional Research Collaboration Agreement
2015
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
AUTM Preliminary Patent Management Agreement
2013
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
AXA Prime Impact Master Fund - Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
2020
Funder
Industry
Diagnostic
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Gates Foundation - Arsanis RSV Monoclonal Antibodies Funding Agreement
2017
Funder
Industry
Drug
Preclinical
Gates Foundation - Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
2017
Funder
Industry
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Gates Foundation - CureVac, Global Access Commitments Agreement
2015
Funder
Industry
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gates Foundation - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
2020
Funder
Industry
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
2021
Funder
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Boston University Startup Exclusive License Template
2012
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
CARB-X Research Subaward Agreement
2019
Academic institution
Funder
Industry
Drug
Preclinical
Early clinical (through Phase 2)
CAVD Data & Materials Sharing Agreement
2006
Academic institution
Funder
Government
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Cellscript - BioNTech mRNA Technology Patent Sublicense
2016
Industry
Vaccine
Preclinical
CEPI CfP3i Vaccine Funding Agreement Template
2018
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
CEPI - CureVac, Framework Partnering Agreement
2019
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
CEPI - Dynavax, COVID-19 Material Reservation Agreement
2021
Funder
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
CEPI - Valneva, Chikungunya Vaccine Funding Agreement
2019
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
2021
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
2020
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
2021
Government
Multilateral organization
Diagnostic
Commercialization
CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
2021
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Drugs For Neglected Diseases Initiative - BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
2009
Industry
Product development partnership
Drug
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
WHO - Manufacturer, Ebola Products Collaboration LOA Template
2015
Multilateral organization
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Elkurt - Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
2021
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Entasis - DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
2017
Industry
Product development partnership
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
FIND Sample Funding Terms and Conditions
2021
Academic institution
Industry
Product development partnership
Diagnostic
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
2021
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Fiocruz - AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
2021
Government
Industry
Vaccine
Commercialization
Funder Development Partnering Agreement Template
2018
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gates Foundation - Icosavax, COVID-19 Vaccine Grant Agreement
2021
Funder
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
2015
Funder
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Gates Foundation Sample Grant Terms & Conditions
2019
Academic institution
Funder
Industry
Product development partnership
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
2021
Industry
Multilateral organization
Vaccine
Late clinical (Phase 3)
Commercialization
Gilead - Indian Generic Manufacturers, HCV License Agreement
2014
Industry
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
IMI 1 Model Grant Agreement
2011
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
IMI 2 JU Model Consortium Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
IMI 2 Model Grant Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Israel - Pfizer, Epidemiological Evidence Collaboration Agreement
2021
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Field Testing
Lambert Toolkit, Consortium Agreement D Template
2019
Academic institution
Industry
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
2014
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
BARDA - Moderna, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
2020
Industry
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
MPP - AbbVie, HIV Antiretroviral License Agreement
2016
Industry
Multilateral organization
Drug
Commercialization
MPP - AbbVie, HIV Antiretroviral Sublicense Agreement
2014
Industry
Multilateral organization
Drug
Commercialization
MPP - BMS - Aurobindo, Daclatasvir Sublicense & Tech Transfer Agreement
2016
Industry
Multilateral organization
Drug
Commercialization
MPP - BMS Sublicense & Tech Transfer Agreement
2017
Industry
Multilateral organization
Drug
Commercialization
Gilead - MPP - Arene Lifesciences, HIV Therapeutic License Agreement
2018
Industry
Multilateral organization
Drug
Commercialization
MPP - Pfizer, Sutezolid License Agreement
2019
Industry
Multilateral organization
Drug
Commercialization
MPP - University of Liverpool, Solid Drug Nanoparticle Technology License Agreement
2015
Academic institution
Multilateral organization
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
MPP - ViiV, Dolutegravir License Agreement
2016
Industry
Multilateral organization
Drug
Commercialization
Merck - MPP, Molnupiravir License Agreement
2021
Industry
Multilateral organization
Drug
Late clinical (Phase 3)
Commercialization
US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
2020
Government
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
NIH - GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
2020
Government
Industry
Vaccine
Preclinical
Commercialization
NIH - Non-Profit, Model License Agreement Terms
2017
Government
Multilateral organization
Product development partnership
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
NIH - MPP, COVID-19 Patent and Biological Material License Agreement
2022
Government
Multilateral organization
Diagnostic
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Vaccine
Commercialization
Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
2020
Industry
Vaccine
Commercialization
US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Academic Institution - Company, Research Collaboration Agreement
2016
Academic institution
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
2020
Government
Industry
Drug
Late clinical (Phase 3)
Commercialization
US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Shionogi - GARDP, Cefiderocol License Agreement
2022
Industry
Product development partnership
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
UnitaidExplore Sample Funding Terms and Conditions
2020
Academic institution
Funder
Industry
Product development partnership
Device
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
University of Washington - Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
2021
Academic institution
Multilateral organization
Drug
Preclinical
US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
2020
Government
Industry
Vaccine
Commercialization
Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
2010
Funder
Industry
Drug
Discovery/Concept
Preclinical
WHO Confidential Disclosure Agreement Template
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Standard Framework MoU
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Template Collaboration Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Template Material Transfer Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
UK Secretary of State - Roche, REGN-COV2 Supply Agreement
2021
Government
Industry
Drug
Late clinical (Phase 3)
Commercialization

				GHIAA2019\MapguideSearch Object
(
    [search_parameters] => 
    [filters] => Array
        (
        )

    [child_filters] => Array
        (
        )

    [agreement_args] => 
    [provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
        )

    [text_agreement_args] => 
    [text_provision_args] => 
    [agreement_ids] => Array
        (
        )

    [agreement_q_rslts] => 
    [provision_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                )

            [query_vars] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [s] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [ignore_sticky_posts] => 
                    [suppress_filters] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [update_menu_item_cache] => 
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [order] => DESC
                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => 
			SELECT   wpry_posts.*
			FROM wpry_posts 
			WHERE 1=1  AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
			
			ORDER BY wpry_posts.post_date DESC
			
		
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 8491
                            [post_author] => 5
                            [post_date] => 2023-01-19 11:34:54
                            [post_date_gmt] => 2023-01-19 11:34:54
                            [post_content] => 
                            [post_title] => CEPI CfP3i Vaccine Funding Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-vaccine-funding-agreement-template
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-19 11:34:54
                            [post_modified_gmt] => 2023-01-19 11:34:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8491
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 8490
                            [post_author] => 5
                            [post_date] => 2023-01-19 11:11:46
                            [post_date_gmt] => 2023-01-19 11:11:46
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-19 11:11:46
                            [post_modified_gmt] => 2023-01-19 11:11:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8490
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 8489
                            [post_author] => 5
                            [post_date] => 2023-01-19 10:44:52
                            [post_date_gmt] => 2023-01-19 10:44:52
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-19 10:44:52
                            [post_modified_gmt] => 2023-01-19 10:44:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8489
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 8488
                            [post_author] => 5
                            [post_date] => 2023-01-19 10:15:15
                            [post_date_gmt] => 2023-01-19 10:15:15
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-19 10:15:15
                            [post_modified_gmt] => 2023-01-19 10:15:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8488
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 8487
                            [post_author] => 5
                            [post_date] => 2023-01-19 09:59:54
                            [post_date_gmt] => 2023-01-19 09:59:54
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-19 09:59:54
                            [post_modified_gmt] => 2023-01-19 09:59:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8487
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 8486
                            [post_author] => 5
                            [post_date] => 2023-01-19 09:46:36
                            [post_date_gmt] => 2023-01-19 09:46:36
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-19 09:46:36
                            [post_modified_gmt] => 2023-01-19 09:46:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8486
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 8485
                            [post_author] => 5
                            [post_date] => 2023-01-19 09:39:38
                            [post_date_gmt] => 2023-01-19 09:39:38
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-19 09:39:38
                            [post_modified_gmt] => 2023-01-19 09:39:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8485
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 8484
                            [post_author] => 5
                            [post_date] => 2023-01-19 09:17:50
                            [post_date_gmt] => 2023-01-19 09:17:50
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-19 09:17:50
                            [post_modified_gmt] => 2023-01-19 09:17:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8484
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 8482
                            [post_author] => 5
                            [post_date] => 2023-01-18 16:32:52
                            [post_date_gmt] => 2023-01-18 16:32:52
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-18 16:32:52
                            [post_modified_gmt] => 2023-01-18 16:32:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8482
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 8481
                            [post_author] => 5
                            [post_date] => 2023-01-18 15:49:38
                            [post_date_gmt] => 2023-01-18 15:49:38
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-19 12:07:24
                            [post_modified_gmt] => 2023-01-19 12:07:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8481
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 8480
                            [post_author] => 5
                            [post_date] => 2023-01-17 17:53:00
                            [post_date_gmt] => 2023-01-17 17:53:00
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-17 17:53:00
                            [post_modified_gmt] => 2023-01-17 17:53:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8480
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 8479
                            [post_author] => 5
                            [post_date] => 2023-01-17 17:35:45
                            [post_date_gmt] => 2023-01-17 17:35:45
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-17 17:35:45
                            [post_modified_gmt] => 2023-01-17 17:35:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8479
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 8469
                            [post_author] => 5
                            [post_date] => 2023-01-13 13:35:47
                            [post_date_gmt] => 2023-01-13 13:35:47
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-13 13:35:47
                            [post_modified_gmt] => 2023-01-13 13:35:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8469
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 8468
                            [post_author] => 5
                            [post_date] => 2023-01-11 14:35:38
                            [post_date_gmt] => 2023-01-11 14:35:38
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-11 14:54:13
                            [post_modified_gmt] => 2023-01-11 14:54:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8468
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 8467
                            [post_author] => 5
                            [post_date] => 2023-01-11 14:29:13
                            [post_date_gmt] => 2023-01-11 14:29:13
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-11 14:36:41
                            [post_modified_gmt] => 2023-01-11 14:36:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8467
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 8462
                            [post_author] => 5
                            [post_date] => 2023-01-10 12:12:52
                            [post_date_gmt] => 2023-01-10 12:12:52
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 12:21:16
                            [post_modified_gmt] => 2023-01-10 12:21:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8462
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 8461
                            [post_author] => 5
                            [post_date] => 2023-01-10 09:08:41
                            [post_date_gmt] => 2023-01-10 09:08:41
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 09:17:07
                            [post_modified_gmt] => 2023-01-10 09:17:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8461
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 8460
                            [post_author] => 5
                            [post_date] => 2023-01-05 12:38:47
                            [post_date_gmt] => 2023-01-05 12:38:47
                            [post_content] => 
                            [post_title] => AUTM Preliminary Patent Management Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-preliminary-patent-management-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-05 12:39:08
                            [post_modified_gmt] => 2023-01-05 12:39:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8460
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 8459
                            [post_author] => 5
                            [post_date] => 2023-01-05 12:24:50
                            [post_date_gmt] => 2023-01-05 12:24:50
                            [post_content] => 
                            [post_title] => AUTM Preliminary Patent Management Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-preliminary-patent-management-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-05 12:24:50
                            [post_modified_gmt] => 2023-01-05 12:24:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8459
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 8458
                            [post_author] => 5
                            [post_date] => 2023-01-05 12:18:04
                            [post_date_gmt] => 2023-01-05 12:18:04
                            [post_content] => 
                            [post_title] => AUTM Preliminary Patent Management Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-preliminary-patent-management-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-05 12:18:04
                            [post_modified_gmt] => 2023-01-05 12:18:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8458
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 8457
                            [post_author] => 5
                            [post_date] => 2023-01-05 12:07:10
                            [post_date_gmt] => 2023-01-05 12:07:10
                            [post_content] => 
                            [post_title] => AUTM Preliminary Patent Management Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-preliminary-patent-management-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-05 12:07:10
                            [post_modified_gmt] => 2023-01-05 12:07:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8457
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 8456
                            [post_author] => 5
                            [post_date] => 2023-01-05 11:54:22
                            [post_date_gmt] => 2023-01-05 11:54:22
                            [post_content] => 
                            [post_title] => AUTM Preliminary Patent Management Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-preliminary-patent-management-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-05 12:08:18
                            [post_modified_gmt] => 2023-01-05 12:08:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8456
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 8447
                            [post_author] => 5
                            [post_date] => 2022-12-15 15:33:22
                            [post_date_gmt] => 2022-12-15 15:33:22
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-government-ology-bioservices-covid-19-plasmid-procurement-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:33:22
                            [post_modified_gmt] => 2022-12-15 15:33:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8447
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 3910
                            [post_author] => 5
                            [post_date] => 2022-12-15 14:44:16
                            [post_date_gmt] => 2022-12-15 14:44:16
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:47:48
                            [post_modified_gmt] => 2023-01-27 14:47:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3910
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 5625
                            [post_author] => 5
                            [post_date] => 2022-12-15 09:51:55
                            [post_date_gmt] => 2022-12-15 09:51:55
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 09:51:55
                            [post_modified_gmt] => 2022-12-15 09:51:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5625
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 8314
                            [post_author] => 5
                            [post_date] => 2022-12-13 11:46:36
                            [post_date_gmt] => 2022-12-13 11:46:36
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 11:46:36
                            [post_modified_gmt] => 2022-12-13 11:46:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8314
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 8313
                            [post_author] => 5
                            [post_date] => 2022-12-13 10:48:56
                            [post_date_gmt] => 2022-12-13 10:48:56
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 10:48:56
                            [post_modified_gmt] => 2022-12-13 10:48:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8313
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 8312
                            [post_author] => 5
                            [post_date] => 2022-12-13 10:35:08
                            [post_date_gmt] => 2022-12-13 10:35:08
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 10:35:08
                            [post_modified_gmt] => 2022-12-13 10:35:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8312
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 8311
                            [post_author] => 5
                            [post_date] => 2022-12-13 10:09:44
                            [post_date_gmt] => 2022-12-13 10:09:44
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 10:09:44
                            [post_modified_gmt] => 2022-12-13 10:09:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8311
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 8192
                            [post_author] => 5
                            [post_date] => 2022-12-13 09:04:26
                            [post_date_gmt] => 2022-12-13 09:04:26
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 09:05:52
                            [post_modified_gmt] => 2022-12-13 09:05:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8192
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [30] => WP_Post Object
                        (
                            [ID] => 8191
                            [post_author] => 5
                            [post_date] => 2022-12-12 16:19:19
                            [post_date_gmt] => 2022-12-12 16:19:19
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 12:55:07
                            [post_modified_gmt] => 2022-12-13 12:55:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8191
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [31] => WP_Post Object
                        (
                            [ID] => 8190
                            [post_author] => 5
                            [post_date] => 2022-12-12 15:29:46
                            [post_date_gmt] => 2022-12-12 15:29:46
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:05:30
                            [post_modified_gmt] => 2022-12-14 13:05:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8190
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [32] => WP_Post Object
                        (
                            [ID] => 8157
                            [post_author] => 5
                            [post_date] => 2022-12-12 15:23:50
                            [post_date_gmt] => 2022-12-12 15:23:50
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 11:29:51
                            [post_modified_gmt] => 2022-12-13 11:29:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8157
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [33] => WP_Post Object
                        (
                            [ID] => 8152
                            [post_author] => 5
                            [post_date] => 2022-12-12 12:04:21
                            [post_date_gmt] => 2022-12-12 12:04:21
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 12:56:37
                            [post_modified_gmt] => 2022-12-13 12:56:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8152
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [34] => WP_Post Object
                        (
                            [ID] => 8151
                            [post_author] => 5
                            [post_date] => 2022-12-12 11:56:08
                            [post_date_gmt] => 2022-12-12 11:56:08
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 13:04:22
                            [post_modified_gmt] => 2022-12-13 13:04:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8151
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [35] => WP_Post Object
                        (
                            [ID] => 8150
                            [post_author] => 5
                            [post_date] => 2022-12-12 11:21:26
                            [post_date_gmt] => 2022-12-12 11:21:26
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-12 11:48:09
                            [post_modified_gmt] => 2022-12-12 11:48:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8150
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [36] => WP_Post Object
                        (
                            [ID] => 8143
                            [post_author] => 5
                            [post_date] => 2022-12-12 11:10:19
                            [post_date_gmt] => 2022-12-12 11:10:19
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-12 11:10:19
                            [post_modified_gmt] => 2022-12-12 11:10:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8143
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [37] => WP_Post Object
                        (
                            [ID] => 8142
                            [post_author] => 5
                            [post_date] => 2022-12-12 10:40:31
                            [post_date_gmt] => 2022-12-12 10:40:31
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 12:57:50
                            [post_modified_gmt] => 2022-12-13 12:57:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8142
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [38] => WP_Post Object
                        (
                            [ID] => 8131
                            [post_author] => 5
                            [post_date] => 2022-12-12 09:57:36
                            [post_date_gmt] => 2022-12-12 09:57:36
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 12:49:55
                            [post_modified_gmt] => 2022-12-13 12:49:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8131
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [39] => WP_Post Object
                        (
                            [ID] => 8130
                            [post_author] => 5
                            [post_date] => 2022-12-12 09:34:49
                            [post_date_gmt] => 2022-12-12 09:34:49
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 12:51:49
                            [post_modified_gmt] => 2022-12-13 12:51:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8130
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [40] => WP_Post Object
                        (
                            [ID] => 8129
                            [post_author] => 5
                            [post_date] => 2022-12-12 08:55:53
                            [post_date_gmt] => 2022-12-12 08:55:53
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-13 12:45:31
                            [post_modified_gmt] => 2022-12-13 12:45:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8129
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [41] => WP_Post Object
                        (
                            [ID] => 8051
                            [post_author] => 5
                            [post_date] => 2022-12-12 08:39:19
                            [post_date_gmt] => 2022-12-12 08:39:19
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 13:54:45
                            [post_modified_gmt] => 2023-01-10 13:54:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8051
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [42] => WP_Post Object
                        (
                            [ID] => 7582
                            [post_author] => 5
                            [post_date] => 2022-12-08 08:48:17
                            [post_date_gmt] => 2022-12-08 08:48:17
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-08 08:48:17
                            [post_modified_gmt] => 2022-12-08 08:48:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7582
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [43] => WP_Post Object
                        (
                            [ID] => 7581
                            [post_author] => 5
                            [post_date] => 2022-12-08 08:20:09
                            [post_date_gmt] => 2022-12-08 08:20:09
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-08 08:20:09
                            [post_modified_gmt] => 2022-12-08 08:20:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7581
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [44] => WP_Post Object
                        (
                            [ID] => 7580
                            [post_author] => 5
                            [post_date] => 2022-12-08 08:14:21
                            [post_date_gmt] => 2022-12-08 08:14:21
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-08 08:14:21
                            [post_modified_gmt] => 2022-12-08 08:14:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7580
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [45] => WP_Post Object
                        (
                            [ID] => 7570
                            [post_author] => 5
                            [post_date] => 2022-12-07 16:44:09
                            [post_date_gmt] => 2022-12-07 16:44:09
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-07 16:44:09
                            [post_modified_gmt] => 2022-12-07 16:44:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7570
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [46] => WP_Post Object
                        (
                            [ID] => 7569
                            [post_author] => 5
                            [post_date] => 2022-12-07 16:39:11
                            [post_date_gmt] => 2022-12-07 16:39:11
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-07 16:39:11
                            [post_modified_gmt] => 2022-12-07 16:39:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7569
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [47] => WP_Post Object
                        (
                            [ID] => 7568
                            [post_author] => 5
                            [post_date] => 2022-12-07 16:18:53
                            [post_date_gmt] => 2022-12-07 16:18:53
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-07 16:18:53
                            [post_modified_gmt] => 2022-12-07 16:18:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7568
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [48] => WP_Post Object
                        (
                            [ID] => 7567
                            [post_author] => 5
                            [post_date] => 2022-12-07 16:14:54
                            [post_date_gmt] => 2022-12-07 16:14:54
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-07 16:15:28
                            [post_modified_gmt] => 2022-12-07 16:15:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7567
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [49] => WP_Post Object
                        (
                            [ID] => 7563
                            [post_author] => 5
                            [post_date] => 2022-12-07 16:00:00
                            [post_date_gmt] => 2022-12-07 16:00:00
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-07 16:00:00
                            [post_modified_gmt] => 2022-12-07 16:00:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7563
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [50] => WP_Post Object
                        (
                            [ID] => 7562
                            [post_author] => 5
                            [post_date] => 2022-12-07 15:26:44
                            [post_date_gmt] => 2022-12-07 15:26:44
                            [post_content] => 
                            [post_title] => FIND Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => find-sample-funding-terms-and-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-07 15:30:21
                            [post_modified_gmt] => 2022-12-07 15:30:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7562
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [51] => WP_Post Object
                        (
                            [ID] => 7468
                            [post_author] => 5
                            [post_date] => 2022-12-05 12:56:35
                            [post_date_gmt] => 2022-12-05 12:56:35
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-05 12:56:35
                            [post_modified_gmt] => 2022-12-05 12:56:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7468
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [52] => WP_Post Object
                        (
                            [ID] => 7467
                            [post_author] => 5
                            [post_date] => 2022-12-05 12:50:39
                            [post_date_gmt] => 2022-12-05 12:50:39
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-05 12:50:39
                            [post_modified_gmt] => 2022-12-05 12:50:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7467
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [53] => WP_Post Object
                        (
                            [ID] => 7466
                            [post_author] => 5
                            [post_date] => 2022-12-05 12:39:45
                            [post_date_gmt] => 2022-12-05 12:39:45
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-05 12:39:45
                            [post_modified_gmt] => 2022-12-05 12:39:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7466
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [54] => WP_Post Object
                        (
                            [ID] => 7464
                            [post_author] => 5
                            [post_date] => 2022-12-05 11:38:57
                            [post_date_gmt] => 2022-12-05 11:38:57
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-05 11:38:57
                            [post_modified_gmt] => 2022-12-05 11:38:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7464
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [55] => WP_Post Object
                        (
                            [ID] => 7445
                            [post_author] => 5
                            [post_date] => 2022-12-05 11:10:08
                            [post_date_gmt] => 2022-12-05 11:10:08
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-05 11:10:08
                            [post_modified_gmt] => 2022-12-05 11:10:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7445
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [56] => WP_Post Object
                        (
                            [ID] => 7463
                            [post_author] => 5
                            [post_date] => 2022-12-05 10:28:51
                            [post_date_gmt] => 2022-12-05 10:28:51
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-05 10:28:51
                            [post_modified_gmt] => 2022-12-05 10:28:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7463
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [57] => WP_Post Object
                        (
                            [ID] => 7462
                            [post_author] => 5
                            [post_date] => 2022-12-05 10:15:17
                            [post_date_gmt] => 2022-12-05 10:15:17
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-05 10:17:16
                            [post_modified_gmt] => 2022-12-05 10:17:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7462
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [58] => WP_Post Object
                        (
                            [ID] => 7444
                            [post_author] => 5
                            [post_date] => 2022-12-01 14:17:31
                            [post_date_gmt] => 2022-12-01 14:17:31
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-01 14:19:12
                            [post_modified_gmt] => 2022-12-01 14:19:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7444
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [59] => WP_Post Object
                        (
                            [ID] => 7443
                            [post_author] => 5
                            [post_date] => 2022-12-01 11:47:54
                            [post_date_gmt] => 2022-12-01 11:47:54
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-01 14:53:17
                            [post_modified_gmt] => 2022-12-01 14:53:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7443
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [60] => WP_Post Object
                        (
                            [ID] => 7442
                            [post_author] => 5
                            [post_date] => 2022-12-01 11:26:45
                            [post_date_gmt] => 2022-12-01 11:26:45
                            [post_content] => 
                            [post_title] => UnitaidExplore Sample Funding Terms and Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => unitaidexplore-sample-funding-terms-and-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-05 12:57:58
                            [post_modified_gmt] => 2022-12-05 12:57:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=7442
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [61] => WP_Post Object
                        (
                            [ID] => 6638
                            [post_author] => 5
                            [post_date] => 2022-11-09 13:48:21
                            [post_date_gmt] => 2022-11-09 13:48:21
                            [post_content] => 
                            [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-09 13:49:21
                            [post_modified_gmt] => 2022-11-09 13:49:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6638
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [62] => WP_Post Object
                        (
                            [ID] => 6637
                            [post_author] => 5
                            [post_date] => 2022-11-09 13:40:00
                            [post_date_gmt] => 2022-11-09 13:40:00
                            [post_content] => 
                            [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-09 13:40:00
                            [post_modified_gmt] => 2022-11-09 13:40:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6637
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [63] => WP_Post Object
                        (
                            [ID] => 6636
                            [post_author] => 5
                            [post_date] => 2022-11-09 13:21:22
                            [post_date_gmt] => 2022-11-09 13:21:22
                            [post_content] => 
                            [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-09 13:21:22
                            [post_modified_gmt] => 2022-11-09 13:21:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6636
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [64] => WP_Post Object
                        (
                            [ID] => 6635
                            [post_author] => 5
                            [post_date] => 2022-11-09 13:05:41
                            [post_date_gmt] => 2022-11-09 13:05:41
                            [post_content] => 
                            [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-24 13:11:43
                            [post_modified_gmt] => 2023-01-24 13:11:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6635
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [65] => WP_Post Object
                        (
                            [ID] => 6634
                            [post_author] => 5
                            [post_date] => 2022-11-08 19:23:52
                            [post_date_gmt] => 2022-11-08 19:23:52
                            [post_content] => 
                            [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-08 19:23:52
                            [post_modified_gmt] => 2022-11-08 19:23:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6634
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [66] => WP_Post Object
                        (
                            [ID] => 6633
                            [post_author] => 5
                            [post_date] => 2022-11-08 19:03:56
                            [post_date_gmt] => 2022-11-08 19:03:56
                            [post_content] => 
                            [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-08 19:03:56
                            [post_modified_gmt] => 2022-11-08 19:03:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6633
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [67] => WP_Post Object
                        (
                            [ID] => 6632
                            [post_author] => 5
                            [post_date] => 2022-11-08 18:14:54
                            [post_date_gmt] => 2022-11-08 18:14:54
                            [post_content] => 
                            [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-08 18:15:07
                            [post_modified_gmt] => 2022-11-08 18:15:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6632
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [68] => WP_Post Object
                        (
                            [ID] => 6631
                            [post_author] => 5
                            [post_date] => 2022-11-08 16:07:28
                            [post_date_gmt] => 2022-11-08 16:07:28
                            [post_content] => 
                            [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-08 19:18:32
                            [post_modified_gmt] => 2022-11-08 19:18:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6631
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [69] => WP_Post Object
                        (
                            [ID] => 6630
                            [post_author] => 5
                            [post_date] => 2022-11-08 15:22:11
                            [post_date_gmt] => 2022-11-08 15:22:11
                            [post_content] => 
                            [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-08 18:15:51
                            [post_modified_gmt] => 2022-11-08 18:15:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6630
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [70] => WP_Post Object
                        (
                            [ID] => 6629
                            [post_author] => 5
                            [post_date] => 2022-11-08 14:54:13
                            [post_date_gmt] => 2022-11-08 14:54:13
                            [post_content] => 
                            [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-08 14:54:13
                            [post_modified_gmt] => 2022-11-08 14:54:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6629
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [71] => WP_Post Object
                        (
                            [ID] => 6628
                            [post_author] => 5
                            [post_date] => 2022-11-08 13:12:06
                            [post_date_gmt] => 2022-11-08 13:12:06
                            [post_content] => 
                            [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-08 19:04:36
                            [post_modified_gmt] => 2022-11-08 19:04:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6628
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [72] => WP_Post Object
                        (
                            [ID] => 6333
                            [post_author] => 5
                            [post_date] => 2022-10-27 15:17:29
                            [post_date_gmt] => 2022-10-27 15:17:29
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-27 15:17:29
                            [post_modified_gmt] => 2022-10-27 15:17:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6333
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [73] => WP_Post Object
                        (
                            [ID] => 6332
                            [post_author] => 5
                            [post_date] => 2022-10-27 15:11:17
                            [post_date_gmt] => 2022-10-27 15:11:17
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-27 15:11:17
                            [post_modified_gmt] => 2022-10-27 15:11:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6332
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [74] => WP_Post Object
                        (
                            [ID] => 6330
                            [post_author] => 5
                            [post_date] => 2022-10-27 15:05:13
                            [post_date_gmt] => 2022-10-27 15:05:13
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-27 15:05:13
                            [post_modified_gmt] => 2022-10-27 15:05:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6330
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [75] => WP_Post Object
                        (
                            [ID] => 6329
                            [post_author] => 5
                            [post_date] => 2022-10-27 11:59:35
                            [post_date_gmt] => 2022-10-27 11:59:35
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-27 12:01:16
                            [post_modified_gmt] => 2022-10-27 12:01:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6329
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [76] => WP_Post Object
                        (
                            [ID] => 6328
                            [post_author] => 5
                            [post_date] => 2022-10-27 11:49:09
                            [post_date_gmt] => 2022-10-27 11:49:09
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-27 11:49:09
                            [post_modified_gmt] => 2022-10-27 11:49:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6328
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [77] => WP_Post Object
                        (
                            [ID] => 6327
                            [post_author] => 5
                            [post_date] => 2022-10-27 11:45:45
                            [post_date_gmt] => 2022-10-27 11:45:45
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-27 11:45:45
                            [post_modified_gmt] => 2022-10-27 11:45:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6327
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [78] => WP_Post Object
                        (
                            [ID] => 6326
                            [post_author] => 5
                            [post_date] => 2022-10-27 11:13:28
                            [post_date_gmt] => 2022-10-27 11:13:28
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-27 11:13:28
                            [post_modified_gmt] => 2022-10-27 11:13:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6326
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [79] => WP_Post Object
                        (
                            [ID] => 6325
                            [post_author] => 5
                            [post_date] => 2022-10-27 10:57:10
                            [post_date_gmt] => 2022-10-27 10:57:10
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-27 10:57:10
                            [post_modified_gmt] => 2022-10-27 10:57:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6325
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [80] => WP_Post Object
                        (
                            [ID] => 6324
                            [post_author] => 5
                            [post_date] => 2022-10-27 10:23:50
                            [post_date_gmt] => 2022-10-27 10:23:50
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-27 10:23:50
                            [post_modified_gmt] => 2022-10-27 10:23:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6324
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [81] => WP_Post Object
                        (
                            [ID] => 6323
                            [post_author] => 5
                            [post_date] => 2022-10-27 09:37:11
                            [post_date_gmt] => 2022-10-27 09:37:11
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-27 09:37:11
                            [post_modified_gmt] => 2022-10-27 09:37:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6323
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [82] => WP_Post Object
                        (
                            [ID] => 6322
                            [post_author] => 5
                            [post_date] => 2022-10-27 09:13:33
                            [post_date_gmt] => 2022-10-27 09:13:33
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-27 09:51:03
                            [post_modified_gmt] => 2022-10-27 09:51:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6322
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [83] => WP_Post Object
                        (
                            [ID] => 6319
                            [post_author] => 5
                            [post_date] => 2022-10-26 13:16:20
                            [post_date_gmt] => 2022-10-26 13:16:20
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-26 13:16:20
                            [post_modified_gmt] => 2022-10-26 13:16:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6319
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [84] => WP_Post Object
                        (
                            [ID] => 6318
                            [post_author] => 5
                            [post_date] => 2022-10-26 13:08:20
                            [post_date_gmt] => 2022-10-26 13:08:20
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-26 13:08:20
                            [post_modified_gmt] => 2022-10-26 13:08:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6318
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [85] => WP_Post Object
                        (
                            [ID] => 6317
                            [post_author] => 5
                            [post_date] => 2022-10-26 12:22:38
                            [post_date_gmt] => 2022-10-26 12:22:38
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-27 15:23:44
                            [post_modified_gmt] => 2022-10-27 15:23:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6317
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [86] => WP_Post Object
                        (
                            [ID] => 6316
                            [post_author] => 5
                            [post_date] => 2022-10-26 11:26:56
                            [post_date_gmt] => 2022-10-26 11:26:56
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-27 15:21:49
                            [post_modified_gmt] => 2022-10-27 15:21:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6316
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [87] => WP_Post Object
                        (
                            [ID] => 6315
                            [post_author] => 5
                            [post_date] => 2022-10-26 10:20:15
                            [post_date_gmt] => 2022-10-26 10:20:15
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative - BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-27 15:22:46
                            [post_modified_gmt] => 2022-10-27 15:22:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6315
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [88] => WP_Post Object
                        (
                            [ID] => 6314
                            [post_author] => 5
                            [post_date] => 2022-10-26 10:01:08
                            [post_date_gmt] => 2022-10-26 10:01:08
                            [post_content] => 
                            [post_title] => Drugs For Neglected Diseases Initiative - BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-27 15:19:13
                            [post_modified_gmt] => 2022-10-27 15:19:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6314
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [89] => WP_Post Object
                        (
                            [ID] => 6289
                            [post_author] => 5
                            [post_date] => 2022-10-26 07:36:18
                            [post_date_gmt] => 2022-10-26 07:36:18
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-26 07:36:19
                            [post_modified_gmt] => 2022-10-26 07:36:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6289
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [90] => WP_Post Object
                        (
                            [ID] => 6288
                            [post_author] => 5
                            [post_date] => 2022-10-26 06:46:06
                            [post_date_gmt] => 2022-10-26 06:46:06
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-26 06:47:52
                            [post_modified_gmt] => 2022-10-26 06:47:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6288
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [91] => WP_Post Object
                        (
                            [ID] => 6287
                            [post_author] => 5
                            [post_date] => 2022-10-25 15:22:03
                            [post_date_gmt] => 2022-10-25 15:22:03
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-25 15:22:03
                            [post_modified_gmt] => 2022-10-25 15:22:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6287
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [92] => WP_Post Object
                        (
                            [ID] => 6286
                            [post_author] => 5
                            [post_date] => 2022-10-25 15:16:07
                            [post_date_gmt] => 2022-10-25 15:16:07
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-25 15:17:06
                            [post_modified_gmt] => 2022-10-25 15:17:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6286
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [93] => WP_Post Object
                        (
                            [ID] => 6285
                            [post_author] => 5
                            [post_date] => 2022-10-25 15:01:54
                            [post_date_gmt] => 2022-10-25 15:01:54
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-25 15:01:54
                            [post_modified_gmt] => 2022-10-25 15:01:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6285
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [94] => WP_Post Object
                        (
                            [ID] => 6284
                            [post_author] => 5
                            [post_date] => 2022-10-25 14:47:20
                            [post_date_gmt] => 2022-10-25 14:47:20
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-25 14:55:56
                            [post_modified_gmt] => 2022-10-25 14:55:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6284
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [95] => WP_Post Object
                        (
                            [ID] => 6283
                            [post_author] => 5
                            [post_date] => 2022-10-25 14:33:12
                            [post_date_gmt] => 2022-10-25 14:33:12
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-26 07:43:58
                            [post_modified_gmt] => 2022-10-26 07:43:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6283
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [96] => WP_Post Object
                        (
                            [ID] => 6282
                            [post_author] => 5
                            [post_date] => 2022-10-25 09:24:40
                            [post_date_gmt] => 2022-10-25 09:24:40
                            [post_content] => 
                            [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-26 07:46:59
                            [post_modified_gmt] => 2022-10-26 07:46:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6282
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [97] => WP_Post Object
                        (
                            [ID] => 6281
                            [post_author] => 5
                            [post_date] => 2022-10-25 08:56:46
                            [post_date_gmt] => 2022-10-25 08:56:46
                            [post_content] => 
                            [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-26 07:53:15
                            [post_modified_gmt] => 2022-10-26 07:53:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6281
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [98] => WP_Post Object
                        (
                            [ID] => 6279
                            [post_author] => 5
                            [post_date] => 2022-10-25 08:07:31
                            [post_date_gmt] => 2022-10-25 08:07:31
                            [post_content] => 
                            [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-25 08:09:52
                            [post_modified_gmt] => 2022-10-25 08:09:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6279
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [99] => WP_Post Object
                        (
                            [ID] => 6278
                            [post_author] => 5
                            [post_date] => 2022-10-25 07:59:13
                            [post_date_gmt] => 2022-10-25 07:59:13
                            [post_content] => 
                            [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-26 07:48:16
                            [post_modified_gmt] => 2022-10-26 07:48:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6278
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [100] => WP_Post Object
                        (
                            [ID] => 6277
                            [post_author] => 5
                            [post_date] => 2022-10-25 07:51:55
                            [post_date_gmt] => 2022-10-25 07:51:55
                            [post_content] => 
                            [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-25 08:10:37
                            [post_modified_gmt] => 2022-10-25 08:10:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6277
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [101] => WP_Post Object
                        (
                            [ID] => 6280
                            [post_author] => 5
                            [post_date] => 2022-10-25 07:42:19
                            [post_date_gmt] => 2022-10-25 07:42:19
                            [post_content] => 
                            [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-26 07:57:26
                            [post_modified_gmt] => 2022-10-26 07:57:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6280
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [102] => WP_Post Object
                        (
                            [ID] => 6276
                            [post_author] => 5
                            [post_date] => 2022-10-25 07:37:13
                            [post_date_gmt] => 2022-10-25 07:37:13
                            [post_content] => 
                            [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-26 07:54:26
                            [post_modified_gmt] => 2022-10-26 07:54:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=6276
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [103] => WP_Post Object
                        (
                            [ID] => 5829
                            [post_author] => 5
                            [post_date] => 2022-10-11 12:04:17
                            [post_date_gmt] => 2022-10-11 12:04:17
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:04:17
                            [post_modified_gmt] => 2022-10-11 12:04:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5829
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [104] => WP_Post Object
                        (
                            [ID] => 5828
                            [post_author] => 5
                            [post_date] => 2022-10-11 11:14:22
                            [post_date_gmt] => 2022-10-11 11:14:22
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 11:14:22
                            [post_modified_gmt] => 2022-10-11 11:14:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5828
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [105] => WP_Post Object
                        (
                            [ID] => 5827
                            [post_author] => 5
                            [post_date] => 2022-10-11 10:21:39
                            [post_date_gmt] => 2022-10-11 10:21:39
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 10:21:39
                            [post_modified_gmt] => 2022-10-11 10:21:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5827
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [106] => WP_Post Object
                        (
                            [ID] => 5814
                            [post_author] => 5
                            [post_date] => 2022-10-05 16:01:43
                            [post_date_gmt] => 2022-10-05 16:01:43
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-05 16:01:43
                            [post_modified_gmt] => 2022-10-05 16:01:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5814
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [107] => WP_Post Object
                        (
                            [ID] => 5813
                            [post_author] => 5
                            [post_date] => 2022-10-05 15:37:35
                            [post_date_gmt] => 2022-10-05 15:37:35
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-05 15:37:35
                            [post_modified_gmt] => 2022-10-05 15:37:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5813
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [108] => WP_Post Object
                        (
                            [ID] => 5812
                            [post_author] => 5
                            [post_date] => 2022-10-05 14:34:35
                            [post_date_gmt] => 2022-10-05 14:34:35
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-05 14:34:35
                            [post_modified_gmt] => 2022-10-05 14:34:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5812
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [109] => WP_Post Object
                        (
                            [ID] => 5811
                            [post_author] => 5
                            [post_date] => 2022-10-05 13:31:14
                            [post_date_gmt] => 2022-10-05 13:31:14
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-05 13:31:14
                            [post_modified_gmt] => 2022-10-05 13:31:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5811
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [110] => WP_Post Object
                        (
                            [ID] => 5810
                            [post_author] => 5
                            [post_date] => 2022-10-05 12:10:58
                            [post_date_gmt] => 2022-10-05 12:10:58
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 09:51:05
                            [post_modified_gmt] => 2022-10-11 09:51:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5810
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [111] => WP_Post Object
                        (
                            [ID] => 5807
                            [post_author] => 5
                            [post_date] => 2022-10-05 10:53:32
                            [post_date_gmt] => 2022-10-05 10:53:32
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 09:43:25
                            [post_modified_gmt] => 2022-10-11 09:43:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5807
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [112] => WP_Post Object
                        (
                            [ID] => 5809
                            [post_author] => 5
                            [post_date] => 2022-10-05 07:50:36
                            [post_date_gmt] => 2022-10-05 07:50:36
                            [post_content] => 
                            [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-05 07:50:36
                            [post_modified_gmt] => 2022-10-05 07:50:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5809
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [113] => WP_Post Object
                        (
                            [ID] => 5808
                            [post_author] => 5
                            [post_date] => 2022-10-04 10:04:03
                            [post_date_gmt] => 2022-10-04 10:04:03
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-04 10:04:03
                            [post_modified_gmt] => 2022-10-04 10:04:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5808
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [114] => WP_Post Object
                        (
                            [ID] => 5806
                            [post_author] => 5
                            [post_date] => 2022-09-28 14:56:08
                            [post_date_gmt] => 2022-09-28 14:56:08
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-28 14:56:08
                            [post_modified_gmt] => 2022-09-28 14:56:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5806
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [115] => WP_Post Object
                        (
                            [ID] => 5805
                            [post_author] => 5
                            [post_date] => 2022-09-28 14:49:39
                            [post_date_gmt] => 2022-09-28 14:49:39
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 09:15:29
                            [post_modified_gmt] => 2022-09-29 09:15:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5805
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [116] => WP_Post Object
                        (
                            [ID] => 5804
                            [post_author] => 5
                            [post_date] => 2022-09-28 08:20:57
                            [post_date_gmt] => 2022-09-28 08:20:57
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-28 08:20:57
                            [post_modified_gmt] => 2022-09-28 08:20:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5804
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [117] => WP_Post Object
                        (
                            [ID] => 5803
                            [post_author] => 5
                            [post_date] => 2022-09-28 08:09:22
                            [post_date_gmt] => 2022-09-28 08:09:22
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-28 08:09:22
                            [post_modified_gmt] => 2022-09-28 08:09:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5803
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [118] => WP_Post Object
                        (
                            [ID] => 5802
                            [post_author] => 5
                            [post_date] => 2022-09-28 08:03:24
                            [post_date_gmt] => 2022-09-28 08:03:24
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 09:02:04
                            [post_modified_gmt] => 2022-09-29 09:02:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5802
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [119] => WP_Post Object
                        (
                            [ID] => 5800
                            [post_author] => 5
                            [post_date] => 2022-09-28 07:45:10
                            [post_date_gmt] => 2022-09-28 07:45:10
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 08:30:10
                            [post_modified_gmt] => 2022-09-29 08:30:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5800
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [120] => WP_Post Object
                        (
                            [ID] => 5799
                            [post_author] => 5
                            [post_date] => 2022-09-27 13:35:42
                            [post_date_gmt] => 2022-09-27 13:35:42
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-27 13:35:42
                            [post_modified_gmt] => 2022-09-27 13:35:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5799
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [121] => WP_Post Object
                        (
                            [ID] => 5798
                            [post_author] => 5
                            [post_date] => 2022-09-27 13:11:04
                            [post_date_gmt] => 2022-09-27 13:11:04
                            [post_content] => 
                            [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 07:20:44
                            [post_modified_gmt] => 2022-09-29 07:20:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5798
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [122] => WP_Post Object
                        (
                            [ID] => 5790
                            [post_author] => 5
                            [post_date] => 2022-09-27 09:01:33
                            [post_date_gmt] => 2022-09-27 09:01:33
                            [post_content] => 
                            [post_title] => Gilead - MPP - Arene Lifesciences, HIV Therapeutic License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-mpp-tdf-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 07:30:12
                            [post_modified_gmt] => 2022-09-29 07:30:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5790
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [123] => WP_Post Object
                        (
                            [ID] => 5782
                            [post_author] => 5
                            [post_date] => 2022-09-16 07:28:56
                            [post_date_gmt] => 2022-09-16 07:28:56
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 13:52:08
                            [post_modified_gmt] => 2023-01-10 13:52:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5782
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [124] => WP_Post Object
                        (
                            [ID] => 5781
                            [post_author] => 5
                            [post_date] => 2022-09-14 13:33:43
                            [post_date_gmt] => 2022-09-14 13:33:43
                            [post_content] => 
                            [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-14 13:33:43
                            [post_modified_gmt] => 2022-09-14 13:33:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5781
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [125] => WP_Post Object
                        (
                            [ID] => 5779
                            [post_author] => 5
                            [post_date] => 2022-09-14 13:01:55
                            [post_date_gmt] => 2022-09-14 13:01:55
                            [post_content] => 
                            [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-14 13:31:15
                            [post_modified_gmt] => 2022-09-14 13:31:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5779
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [126] => WP_Post Object
                        (
                            [ID] => 5778
                            [post_author] => 5
                            [post_date] => 2022-09-14 11:49:49
                            [post_date_gmt] => 2022-09-14 11:49:49
                            [post_content] => 
                            [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-20 13:55:31
                            [post_modified_gmt] => 2022-09-20 13:55:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5778
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [127] => WP_Post Object
                        (
                            [ID] => 5777
                            [post_author] => 5
                            [post_date] => 2022-09-14 11:30:25
                            [post_date_gmt] => 2022-09-14 11:30:25
                            [post_content] => 
                            [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-14 11:30:25
                            [post_modified_gmt] => 2022-09-14 11:30:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5777
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [128] => WP_Post Object
                        (
                            [ID] => 5776
                            [post_author] => 5
                            [post_date] => 2022-09-14 11:17:28
                            [post_date_gmt] => 2022-09-14 11:17:28
                            [post_content] => 
                            [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-22 13:21:09
                            [post_modified_gmt] => 2022-09-22 13:21:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5776
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [129] => WP_Post Object
                        (
                            [ID] => 5775
                            [post_author] => 5
                            [post_date] => 2022-09-13 13:17:53
                            [post_date_gmt] => 2022-09-13 13:17:53
                            [post_content] => 
                            [post_title] => AXA Prime Impact Master Fund - Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-24 13:15:19
                            [post_modified_gmt] => 2023-01-24 13:15:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5775
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [130] => WP_Post Object
                        (
                            [ID] => 5700
                            [post_author] => 5
                            [post_date] => 2022-09-07 11:00:26
                            [post_date_gmt] => 2022-09-07 11:00:26
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-07 11:00:26
                            [post_modified_gmt] => 2022-09-07 11:00:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5700
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [131] => WP_Post Object
                        (
                            [ID] => 5699
                            [post_author] => 5
                            [post_date] => 2022-09-07 10:28:24
                            [post_date_gmt] => 2022-09-07 10:28:24
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-07 10:39:35
                            [post_modified_gmt] => 2022-09-07 10:39:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5699
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [132] => WP_Post Object
                        (
                            [ID] => 5698
                            [post_author] => 5
                            [post_date] => 2022-09-07 10:14:27
                            [post_date_gmt] => 2022-09-07 10:14:27
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-07 10:14:27
                            [post_modified_gmt] => 2022-09-07 10:14:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5698
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [133] => WP_Post Object
                        (
                            [ID] => 5697
                            [post_author] => 5
                            [post_date] => 2022-09-07 10:01:19
                            [post_date_gmt] => 2022-09-07 10:01:19
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-07 10:01:19
                            [post_modified_gmt] => 2022-09-07 10:01:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5697
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [134] => WP_Post Object
                        (
                            [ID] => 5696
                            [post_author] => 5
                            [post_date] => 2022-09-07 09:45:07
                            [post_date_gmt] => 2022-09-07 09:45:07
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-07 09:45:07
                            [post_modified_gmt] => 2022-09-07 09:45:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5696
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [135] => WP_Post Object
                        (
                            [ID] => 5695
                            [post_author] => 5
                            [post_date] => 2022-09-07 09:35:25
                            [post_date_gmt] => 2022-09-07 09:35:25
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 10:38:40
                            [post_modified_gmt] => 2022-09-29 10:38:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5695
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [136] => WP_Post Object
                        (
                            [ID] => 5694
                            [post_author] => 5
                            [post_date] => 2022-09-07 09:11:50
                            [post_date_gmt] => 2022-09-07 09:11:50
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-07 11:03:43
                            [post_modified_gmt] => 2022-09-07 11:03:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5694
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [137] => WP_Post Object
                        (
                            [ID] => 5693
                            [post_author] => 5
                            [post_date] => 2022-09-07 08:51:55
                            [post_date_gmt] => 2022-09-07 08:51:55
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:37:31
                            [post_modified_gmt] => 2022-12-14 13:37:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5693
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [138] => WP_Post Object
                        (
                            [ID] => 5692
                            [post_author] => 5
                            [post_date] => 2022-09-07 08:21:55
                            [post_date_gmt] => 2022-09-07 08:21:55
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-07 08:21:55
                            [post_modified_gmt] => 2022-09-07 08:21:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5692
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [139] => WP_Post Object
                        (
                            [ID] => 5691
                            [post_author] => 5
                            [post_date] => 2022-09-07 08:12:00
                            [post_date_gmt] => 2022-09-07 08:12:00
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-07 11:05:55
                            [post_modified_gmt] => 2022-09-07 11:05:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5691
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [140] => WP_Post Object
                        (
                            [ID] => 5690
                            [post_author] => 5
                            [post_date] => 2022-09-06 18:19:25
                            [post_date_gmt] => 2022-09-06 18:19:25
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-06 18:19:25
                            [post_modified_gmt] => 2022-09-06 18:19:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5690
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [141] => WP_Post Object
                        (
                            [ID] => 5689
                            [post_author] => 5
                            [post_date] => 2022-09-06 18:09:28
                            [post_date_gmt] => 2022-09-06 18:09:28
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-06 18:09:28
                            [post_modified_gmt] => 2022-09-06 18:09:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5689
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [142] => WP_Post Object
                        (
                            [ID] => 5688
                            [post_author] => 5
                            [post_date] => 2022-09-06 13:35:23
                            [post_date_gmt] => 2022-09-06 13:35:23
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-07 11:02:05
                            [post_modified_gmt] => 2022-09-07 11:02:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5688
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [143] => WP_Post Object
                        (
                            [ID] => 5684
                            [post_author] => 5
                            [post_date] => 2022-09-06 13:25:46
                            [post_date_gmt] => 2022-09-06 13:25:46
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-06 13:25:46
                            [post_modified_gmt] => 2022-09-06 13:25:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5684
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [144] => WP_Post Object
                        (
                            [ID] => 5683
                            [post_author] => 5
                            [post_date] => 2022-09-06 13:02:35
                            [post_date_gmt] => 2022-09-06 13:02:35
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-07 11:11:54
                            [post_modified_gmt] => 2022-09-07 11:11:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5683
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [145] => WP_Post Object
                        (
                            [ID] => 5682
                            [post_author] => 5
                            [post_date] => 2022-09-06 12:46:39
                            [post_date_gmt] => 2022-09-06 12:46:39
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-07 11:07:59
                            [post_modified_gmt] => 2022-09-07 11:07:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5682
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [146] => WP_Post Object
                        (
                            [ID] => 5681
                            [post_author] => 5
                            [post_date] => 2022-09-06 12:09:51
                            [post_date_gmt] => 2022-09-06 12:09:51
                            [post_content] => 
                            [post_title] => Alnylam Pharmaceuticals - University of British Columbia- AlCana Technology, Sponsored Research Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-07 11:10:08
                            [post_modified_gmt] => 2022-09-07 11:10:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5681
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [147] => WP_Post Object
                        (
                            [ID] => 5653
                            [post_author] => 5
                            [post_date] => 2022-08-25 12:56:30
                            [post_date_gmt] => 2022-08-25 12:56:30
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 12:24:08
                            [post_modified_gmt] => 2023-01-10 12:24:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5653
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [148] => WP_Post Object
                        (
                            [ID] => 5652
                            [post_author] => 5
                            [post_date] => 2022-08-25 12:26:53
                            [post_date_gmt] => 2022-08-25 12:26:53
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 11:46:10
                            [post_modified_gmt] => 2023-01-10 11:46:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5652
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [149] => WP_Post Object
                        (
                            [ID] => 5634
                            [post_author] => 5
                            [post_date] => 2022-08-22 13:18:41
                            [post_date_gmt] => 2022-08-22 13:18:41
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-22 13:18:41
                            [post_modified_gmt] => 2022-08-22 13:18:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5634
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [150] => WP_Post Object
                        (
                            [ID] => 5633
                            [post_author] => 5
                            [post_date] => 2022-08-22 13:15:31
                            [post_date_gmt] => 2022-08-22 13:15:31
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 10:49:29
                            [post_modified_gmt] => 2022-09-29 10:49:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5633
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [151] => WP_Post Object
                        (
                            [ID] => 5632
                            [post_author] => 5
                            [post_date] => 2022-08-22 13:03:54
                            [post_date_gmt] => 2022-08-22 13:03:54
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-22 13:03:54
                            [post_modified_gmt] => 2022-08-22 13:03:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5632
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [152] => WP_Post Object
                        (
                            [ID] => 5631
                            [post_author] => 5
                            [post_date] => 2022-08-22 12:52:49
                            [post_date_gmt] => 2022-08-22 12:52:49
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-22 12:52:49
                            [post_modified_gmt] => 2022-08-22 12:52:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5631
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [153] => WP_Post Object
                        (
                            [ID] => 5629
                            [post_author] => 5
                            [post_date] => 2022-08-22 12:19:52
                            [post_date_gmt] => 2022-08-22 12:19:52
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-22 12:28:27
                            [post_modified_gmt] => 2022-08-22 12:28:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5629
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [154] => WP_Post Object
                        (
                            [ID] => 5627
                            [post_author] => 5
                            [post_date] => 2022-08-22 11:56:36
                            [post_date_gmt] => 2022-08-22 11:56:36
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-22 11:56:36
                            [post_modified_gmt] => 2022-08-22 11:56:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5627
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [155] => WP_Post Object
                        (
                            [ID] => 5626
                            [post_author] => 5
                            [post_date] => 2022-08-22 11:12:04
                            [post_date_gmt] => 2022-08-22 11:12:04
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:38:06
                            [post_modified_gmt] => 2022-12-14 13:38:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5626
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [156] => WP_Post Object
                        (
                            [ID] => 5624
                            [post_author] => 5
                            [post_date] => 2022-08-17 08:56:52
                            [post_date_gmt] => 2022-08-17 08:56:52
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-17 08:56:52
                            [post_modified_gmt] => 2022-08-17 08:56:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5624
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [157] => WP_Post Object
                        (
                            [ID] => 5623
                            [post_author] => 5
                            [post_date] => 2022-08-16 15:29:11
                            [post_date_gmt] => 2022-08-16 15:29:11
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-20 12:53:18
                            [post_modified_gmt] => 2022-09-20 12:53:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5623
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [158] => WP_Post Object
                        (
                            [ID] => 5622
                            [post_author] => 5
                            [post_date] => 2022-08-16 14:49:36
                            [post_date_gmt] => 2022-08-16 14:49:36
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-22 13:07:04
                            [post_modified_gmt] => 2022-08-22 13:07:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5622
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [159] => WP_Post Object
                        (
                            [ID] => 5620
                            [post_author] => 5
                            [post_date] => 2022-08-12 12:05:12
                            [post_date_gmt] => 2022-08-12 12:05:12
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 12:05:12
                            [post_modified_gmt] => 2022-08-12 12:05:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5620
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [160] => WP_Post Object
                        (
                            [ID] => 5619
                            [post_author] => 5
                            [post_date] => 2022-08-12 12:02:21
                            [post_date_gmt] => 2022-08-12 12:02:21
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:48:01
                            [post_modified_gmt] => 2022-10-12 12:48:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5619
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [161] => WP_Post Object
                        (
                            [ID] => 5618
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:52:17
                            [post_date_gmt] => 2022-08-12 11:52:17
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 11:52:17
                            [post_modified_gmt] => 2022-08-12 11:52:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5618
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [162] => WP_Post Object
                        (
                            [ID] => 5617
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:49:46
                            [post_date_gmt] => 2022-08-12 11:49:46
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 11:49:46
                            [post_modified_gmt] => 2022-08-12 11:49:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5617
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [163] => WP_Post Object
                        (
                            [ID] => 5616
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:45:22
                            [post_date_gmt] => 2022-08-12 11:45:22
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 11:45:22
                            [post_modified_gmt] => 2022-08-12 11:45:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5616
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [164] => WP_Post Object
                        (
                            [ID] => 5615
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:40:08
                            [post_date_gmt] => 2022-08-12 11:40:08
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 11:40:08
                            [post_modified_gmt] => 2022-08-12 11:40:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5615
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [165] => WP_Post Object
                        (
                            [ID] => 5614
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:34:41
                            [post_date_gmt] => 2022-08-12 11:34:41
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:28:05
                            [post_modified_gmt] => 2022-09-29 11:28:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5614
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [166] => WP_Post Object
                        (
                            [ID] => 5612
                            [post_author] => 5
                            [post_date] => 2022-08-12 10:14:31
                            [post_date_gmt] => 2022-08-12 10:14:31
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:42:46
                            [post_modified_gmt] => 2022-12-14 13:42:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5612
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [167] => WP_Post Object
                        (
                            [ID] => 5611
                            [post_author] => 5
                            [post_date] => 2022-08-12 10:05:33
                            [post_date_gmt] => 2022-08-12 10:05:33
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 10:05:33
                            [post_modified_gmt] => 2022-08-12 10:05:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5611
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [168] => WP_Post Object
                        (
                            [ID] => 5610
                            [post_author] => 5
                            [post_date] => 2022-08-12 09:31:00
                            [post_date_gmt] => 2022-08-12 09:31:00
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 09:31:00
                            [post_modified_gmt] => 2022-08-12 09:31:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5610
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [169] => WP_Post Object
                        (
                            [ID] => 5609
                            [post_author] => 5
                            [post_date] => 2022-08-12 09:24:43
                            [post_date_gmt] => 2022-08-12 09:24:43
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 09:24:43
                            [post_modified_gmt] => 2022-08-12 09:24:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5609
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [170] => WP_Post Object
                        (
                            [ID] => 5608
                            [post_author] => 5
                            [post_date] => 2022-08-12 09:09:54
                            [post_date_gmt] => 2022-08-12 09:09:54
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-24 12:48:38
                            [post_modified_gmt] => 2023-01-24 12:48:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5608
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [171] => WP_Post Object
                        (
                            [ID] => 5599
                            [post_author] => 5
                            [post_date] => 2022-08-11 14:17:45
                            [post_date_gmt] => 2022-08-11 14:17:45
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-08 12:59:24
                            [post_modified_gmt] => 2022-11-08 12:59:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5599
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [172] => WP_Post Object
                        (
                            [ID] => 5596
                            [post_author] => 5
                            [post_date] => 2022-08-11 12:52:07
                            [post_date_gmt] => 2022-08-11 12:52:07
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-08 18:52:16
                            [post_modified_gmt] => 2022-11-08 18:52:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5596
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [173] => WP_Post Object
                        (
                            [ID] => 5595
                            [post_author] => 5
                            [post_date] => 2022-08-11 12:36:15
                            [post_date_gmt] => 2022-08-11 12:36:15
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 12:36:15
                            [post_modified_gmt] => 2022-08-11 12:36:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5595
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [174] => WP_Post Object
                        (
                            [ID] => 5594
                            [post_author] => 5
                            [post_date] => 2022-08-11 12:13:32
                            [post_date_gmt] => 2022-08-11 12:13:32
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 12:46:35
                            [post_modified_gmt] => 2022-08-11 12:46:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5594
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [175] => WP_Post Object
                        (
                            [ID] => 5593
                            [post_author] => 5
                            [post_date] => 2022-08-11 11:48:52
                            [post_date_gmt] => 2022-08-11 11:48:52
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 12:26:53
                            [post_modified_gmt] => 2022-08-11 12:26:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5593
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [176] => WP_Post Object
                        (
                            [ID] => 5592
                            [post_author] => 5
                            [post_date] => 2022-08-11 11:16:19
                            [post_date_gmt] => 2022-08-11 11:16:19
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 13:12:08
                            [post_modified_gmt] => 2022-10-13 13:12:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5592
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [177] => WP_Post Object
                        (
                            [ID] => 5591
                            [post_author] => 5
                            [post_date] => 2022-08-11 10:18:46
                            [post_date_gmt] => 2022-08-11 10:18:46
                            [post_content] => 
                            [post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 10:18:46
                            [post_modified_gmt] => 2022-08-11 10:18:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5591
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [178] => WP_Post Object
                        (
                            [ID] => 5429
                            [post_author] => 5
                            [post_date] => 2022-07-25 06:51:00
                            [post_date_gmt] => 2022-07-25 06:51:00
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-influenza-and-covid-19-vaccine-collaboration-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:36:35
                            [post_modified_gmt] => 2022-12-14 13:36:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5429
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [179] => WP_Post Object
                        (
                            [ID] => 5427
                            [post_author] => 5
                            [post_date] => 2022-07-22 15:20:29
                            [post_date_gmt] => 2022-07-22 15:20:29
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-05 13:37:17
                            [post_modified_gmt] => 2023-01-05 13:37:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5427
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [180] => WP_Post Object
                        (
                            [ID] => 5286
                            [post_author] => 5
                            [post_date] => 2022-07-08 13:44:08
                            [post_date_gmt] => 2022-07-08 13:44:08
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-18
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-12 11:31:31
                            [post_modified_gmt] => 2022-07-12 11:31:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5286
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [181] => WP_Post Object
                        (
                            [ID] => 5285
                            [post_author] => 5
                            [post_date] => 2022-07-08 13:33:14
                            [post_date_gmt] => 2022-07-08 13:33:14
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-12 11:32:17
                            [post_modified_gmt] => 2022-07-12 11:32:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5285
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [182] => WP_Post Object
                        (
                            [ID] => 5284
                            [post_author] => 5
                            [post_date] => 2022-07-08 13:17:26
                            [post_date_gmt] => 2022-07-08 13:17:26
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-12 11:30:52
                            [post_modified_gmt] => 2022-07-12 11:30:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5284
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [183] => WP_Post Object
                        (
                            [ID] => 5283
                            [post_author] => 5
                            [post_date] => 2022-07-08 13:03:43
                            [post_date_gmt] => 2022-07-08 13:03:43
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-12 11:25:34
                            [post_modified_gmt] => 2022-07-12 11:25:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5283
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [184] => WP_Post Object
                        (
                            [ID] => 5282
                            [post_author] => 5
                            [post_date] => 2022-07-08 13:00:08
                            [post_date_gmt] => 2022-07-08 13:00:08
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:30:18
                            [post_modified_gmt] => 2022-09-29 12:30:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5282
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [185] => WP_Post Object
                        (
                            [ID] => 5281
                            [post_author] => 5
                            [post_date] => 2022-07-08 12:00:54
                            [post_date_gmt] => 2022-07-08 12:00:54
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-11 11:23:37
                            [post_modified_gmt] => 2022-07-11 11:23:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5281
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [186] => WP_Post Object
                        (
                            [ID] => 5280
                            [post_author] => 5
                            [post_date] => 2022-07-08 11:46:11
                            [post_date_gmt] => 2022-07-08 11:46:11
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:03:14
                            [post_modified_gmt] => 2022-10-12 11:03:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5280
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [187] => WP_Post Object
                        (
                            [ID] => 5279
                            [post_author] => 5
                            [post_date] => 2022-07-08 10:36:09
                            [post_date_gmt] => 2022-07-08 10:36:09
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:43:47
                            [post_modified_gmt] => 2022-12-14 13:43:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5279
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [188] => WP_Post Object
                        (
                            [ID] => 5278
                            [post_author] => 5
                            [post_date] => 2022-07-08 10:25:20
                            [post_date_gmt] => 2022-07-08 10:25:20
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-11 11:32:02
                            [post_modified_gmt] => 2022-07-11 11:32:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5278
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [189] => WP_Post Object
                        (
                            [ID] => 5277
                            [post_author] => 5
                            [post_date] => 2022-07-08 10:12:53
                            [post_date_gmt] => 2022-07-08 10:12:53
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-11 13:26:16
                            [post_modified_gmt] => 2022-07-11 13:26:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5277
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [190] => WP_Post Object
                        (
                            [ID] => 5276
                            [post_author] => 5
                            [post_date] => 2022-07-08 10:04:48
                            [post_date_gmt] => 2022-07-08 10:04:48
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-27 09:53:02
                            [post_modified_gmt] => 2022-09-27 09:53:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5276
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [191] => WP_Post Object
                        (
                            [ID] => 5275
                            [post_author] => 5
                            [post_date] => 2022-07-08 09:34:04
                            [post_date_gmt] => 2022-07-08 09:34:04
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-11 12:22:08
                            [post_modified_gmt] => 2022-07-11 12:22:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5275
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [192] => WP_Post Object
                        (
                            [ID] => 5274
                            [post_author] => 5
                            [post_date] => 2022-07-08 09:14:56
                            [post_date_gmt] => 2022-07-08 09:14:56
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:48:27
                            [post_modified_gmt] => 2022-10-12 12:48:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5274
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [193] => WP_Post Object
                        (
                            [ID] => 5273
                            [post_author] => 5
                            [post_date] => 2022-07-08 08:33:17
                            [post_date_gmt] => 2022-07-08 08:33:17
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-11 10:55:22
                            [post_modified_gmt] => 2022-07-11 10:55:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5273
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [194] => WP_Post Object
                        (
                            [ID] => 5272
                            [post_author] => 5
                            [post_date] => 2022-07-08 08:28:02
                            [post_date_gmt] => 2022-07-08 08:28:02
                            [post_content] => 
                            [post_title] => Shionogi – GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-11 10:49:41
                            [post_modified_gmt] => 2022-07-11 10:49:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5272
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [195] => WP_Post Object
                        (
                            [ID] => 5271
                            [post_author] => 5
                            [post_date] => 2022-07-08 08:21:14
                            [post_date_gmt] => 2022-07-08 08:21:14
                            [post_content] => 
                            [post_title] => Shionogi - GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 13:44:53
                            [post_modified_gmt] => 2022-07-13 13:44:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5271
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [196] => WP_Post Object
                        (
                            [ID] => 5270
                            [post_author] => 5
                            [post_date] => 2022-07-08 08:12:42
                            [post_date_gmt] => 2022-07-08 08:12:42
                            [post_content] => 
                            [post_title] => Shionogi - GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 13:14:23
                            [post_modified_gmt] => 2022-10-13 13:14:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5270
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [197] => WP_Post Object
                        (
                            [ID] => 5269
                            [post_author] => 5
                            [post_date] => 2022-07-08 07:47:02
                            [post_date_gmt] => 2022-07-08 07:47:02
                            [post_content] => 
                            [post_title] => Shionogi - GARDP, Cefiderocol License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => shionogi-gardp-cefiderocol-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 11:52:37
                            [post_modified_gmt] => 2022-07-13 11:52:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5269
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [198] => WP_Post Object
                        (
                            [ID] => 5123
                            [post_author] => 5
                            [post_date] => 2022-06-29 15:28:35
                            [post_date_gmt] => 2022-06-29 15:28:35
                            [post_content] => 
                            [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 16:07:24
                            [post_modified_gmt] => 2022-12-14 16:07:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5123
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [199] => WP_Post Object
                        (
                            [ID] => 5122
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:42:34
                            [post_date_gmt] => 2022-06-29 14:42:34
                            [post_content] => 
                            [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 5122
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:03:44
                            [post_modified_gmt] => 2022-10-12 11:03:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5122
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [200] => WP_Post Object
                        (
                            [ID] => 5121
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:38:19
                            [post_date_gmt] => 2022-06-29 14:38:19
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-27 09:30:17
                            [post_modified_gmt] => 2022-09-27 09:30:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5121
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [201] => WP_Post Object
                        (
                            [ID] => 5120
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:30:21
                            [post_date_gmt] => 2022-06-29 14:30:21
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-29 14:30:21
                            [post_modified_gmt] => 2022-06-29 14:30:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5120
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [202] => WP_Post Object
                        (
                            [ID] => 5119
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:09:28
                            [post_date_gmt] => 2022-06-29 14:09:28
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-29 14:09:28
                            [post_modified_gmt] => 2022-06-29 14:09:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5119
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [203] => WP_Post Object
                        (
                            [ID] => 5118
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:05:52
                            [post_date_gmt] => 2022-06-29 14:05:52
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-29 14:05:52
                            [post_modified_gmt] => 2022-06-29 14:05:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5118
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [204] => WP_Post Object
                        (
                            [ID] => 5117
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:02:42
                            [post_date_gmt] => 2022-06-29 14:02:42
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-29 14:02:42
                            [post_modified_gmt] => 2022-06-29 14:02:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5117
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [205] => WP_Post Object
                        (
                            [ID] => 5116
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:00:58
                            [post_date_gmt] => 2022-06-29 14:00:58
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-29 14:00:58
                            [post_modified_gmt] => 2022-06-29 14:00:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5116
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [206] => WP_Post Object
                        (
                            [ID] => 5115
                            [post_author] => 5
                            [post_date] => 2022-06-29 13:52:08
                            [post_date_gmt] => 2022-06-29 13:52:08
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:48:53
                            [post_modified_gmt] => 2022-10-12 12:48:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5115
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [207] => WP_Post Object
                        (
                            [ID] => 5114
                            [post_author] => 5
                            [post_date] => 2022-06-29 13:46:01
                            [post_date_gmt] => 2022-06-29 13:46:01
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-29 15:10:31
                            [post_modified_gmt] => 2022-06-29 15:10:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5114
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [208] => WP_Post Object
                        (
                            [ID] => 5113
                            [post_author] => 5
                            [post_date] => 2022-06-29 13:33:56
                            [post_date_gmt] => 2022-06-29 13:33:56
                            [post_content] => 
                            [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:44:24
                            [post_modified_gmt] => 2022-12-14 13:44:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5113
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [209] => WP_Post Object
                        (
                            [ID] => 5112
                            [post_author] => 5
                            [post_date] => 2022-06-29 13:04:55
                            [post_date_gmt] => 2022-06-29 13:04:55
                            [post_content] => 
                            [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 13:33:12
                            [post_modified_gmt] => 2022-07-13 13:33:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5112
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [210] => WP_Post Object
                        (
                            [ID] => 5111
                            [post_author] => 5
                            [post_date] => 2022-06-29 12:40:35
                            [post_date_gmt] => 2022-06-29 12:40:35
                            [post_content] => 
                            [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 13:13:27
                            [post_modified_gmt] => 2022-10-13 13:13:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5111
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [211] => WP_Post Object
                        (
                            [ID] => 4894
                            [post_author] => 5
                            [post_date] => 2022-06-08 13:01:48
                            [post_date_gmt] => 2022-06-08 13:01:48
                            [post_content] => 
                            [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-09 12:23:23
                            [post_modified_gmt] => 2022-06-09 12:23:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4894
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [212] => WP_Post Object
                        (
                            [ID] => 4893
                            [post_author] => 5
                            [post_date] => 2022-06-08 12:28:46
                            [post_date_gmt] => 2022-06-08 12:28:46
                            [post_content] => 
                            [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-09 12:23:43
                            [post_modified_gmt] => 2022-06-09 12:23:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4893
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [213] => WP_Post Object
                        (
                            [ID] => 4892
                            [post_author] => 5
                            [post_date] => 2022-06-08 11:21:42
                            [post_date_gmt] => 2022-06-08 11:21:42
                            [post_content] => 
                            [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:04:18
                            [post_modified_gmt] => 2022-10-12 11:04:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4892
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [214] => WP_Post Object
                        (
                            [ID] => 4891
                            [post_author] => 5
                            [post_date] => 2022-06-08 10:28:17
                            [post_date_gmt] => 2022-06-08 10:28:17
                            [post_content] => 
                            [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-09 12:28:22
                            [post_modified_gmt] => 2022-06-09 12:28:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4891
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [215] => WP_Post Object
                        (
                            [ID] => 4890
                            [post_author] => 5
                            [post_date] => 2022-06-08 10:10:04
                            [post_date_gmt] => 2022-06-08 10:10:04
                            [post_content] => 
                            [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-09 12:29:11
                            [post_modified_gmt] => 2022-06-09 12:29:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4890
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [216] => WP_Post Object
                        (
                            [ID] => 4889
                            [post_author] => 5
                            [post_date] => 2022-06-08 10:04:27
                            [post_date_gmt] => 2022-06-08 10:04:27
                            [post_content] => 
                            [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-09 12:28:42
                            [post_modified_gmt] => 2022-06-09 12:28:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4889
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [217] => WP_Post Object
                        (
                            [ID] => 4888
                            [post_author] => 5
                            [post_date] => 2022-06-08 09:09:43
                            [post_date_gmt] => 2022-06-08 09:09:43
                            [post_content] => 
                            [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-09 12:28:01
                            [post_modified_gmt] => 2022-06-09 12:28:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4888
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [218] => WP_Post Object
                        (
                            [ID] => 4886
                            [post_author] => 5
                            [post_date] => 2022-06-08 08:43:51
                            [post_date_gmt] => 2022-06-08 08:43:51
                            [post_content] => 
                            [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-09 12:27:40
                            [post_modified_gmt] => 2022-06-09 12:27:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4886
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [219] => WP_Post Object
                        (
                            [ID] => 4885
                            [post_author] => 5
                            [post_date] => 2022-06-08 08:36:01
                            [post_date_gmt] => 2022-06-08 08:36:01
                            [post_content] => 
                            [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:22:57
                            [post_modified_gmt] => 2022-09-29 11:22:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4885
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [220] => WP_Post Object
                        (
                            [ID] => 4884
                            [post_author] => 5
                            [post_date] => 2022-06-08 07:54:05
                            [post_date_gmt] => 2022-06-08 07:54:05
                            [post_content] => 
                            [post_title] => Entasis - DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-09 12:24:23
                            [post_modified_gmt] => 2022-06-09 12:24:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4884
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [221] => WP_Post Object
                        (
                            [ID] => 4883
                            [post_author] => 5
                            [post_date] => 2022-06-08 07:25:31
                            [post_date_gmt] => 2022-06-08 07:25:31
                            [post_content] => 
                            [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-09 12:25:52
                            [post_modified_gmt] => 2022-06-09 12:25:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4883
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [222] => WP_Post Object
                        (
                            [ID] => 4882
                            [post_author] => 5
                            [post_date] => 2022-06-08 07:14:04
                            [post_date_gmt] => 2022-06-08 07:14:04
                            [post_content] => 
                            [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:51:59
                            [post_modified_gmt] => 2022-09-26 14:51:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4882
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [223] => WP_Post Object
                        (
                            [ID] => 4881
                            [post_author] => 5
                            [post_date] => 2022-06-07 13:58:33
                            [post_date_gmt] => 2022-06-07 13:58:33
                            [post_content] => 
                            [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-09 12:25:30
                            [post_modified_gmt] => 2022-06-09 12:25:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4881
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [224] => WP_Post Object
                        (
                            [ID] => 4878
                            [post_author] => 5
                            [post_date] => 2022-06-07 13:47:24
                            [post_date_gmt] => 2022-06-07 13:47:24
                            [post_content] => 
                            [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:49:28
                            [post_modified_gmt] => 2022-10-12 12:49:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4878
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [225] => WP_Post Object
                        (
                            [ID] => 4877
                            [post_author] => 5
                            [post_date] => 2022-06-07 13:22:01
                            [post_date_gmt] => 2022-06-07 13:22:01
                            [post_content] => 
                            [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-09 12:22:56
                            [post_modified_gmt] => 2022-06-09 12:22:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4877
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [226] => WP_Post Object
                        (
                            [ID] => 4876
                            [post_author] => 5
                            [post_date] => 2022-06-07 13:03:57
                            [post_date_gmt] => 2022-06-07 13:03:57
                            [post_content] => 
                            [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 13:00:19
                            [post_modified_gmt] => 2022-07-13 13:00:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4876
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [227] => WP_Post Object
                        (
                            [ID] => 4875
                            [post_author] => 5
                            [post_date] => 2022-06-07 11:48:34
                            [post_date_gmt] => 2022-06-07 11:48:34
                            [post_content] => 
                            [post_title] => Entasis - DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 13:13:57
                            [post_modified_gmt] => 2022-10-13 13:13:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4875
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [228] => WP_Post Object
                        (
                            [ID] => 4873
                            [post_author] => 5
                            [post_date] => 2022-06-07 11:31:58
                            [post_date_gmt] => 2022-06-07 11:31:58
                            [post_content] => 
                            [post_title] => Entasis - DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => entasis-dndi-gardp-gonorrhea-medication-collaboration-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 09:30:15
                            [post_modified_gmt] => 2022-07-13 09:30:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4873
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [229] => WP_Post Object
                        (
                            [ID] => 4869
                            [post_author] => 5
                            [post_date] => 2022-06-07 10:16:47
                            [post_date_gmt] => 2022-06-07 10:16:47
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:50:38
                            [post_modified_gmt] => 2022-10-12 12:50:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4869
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [230] => WP_Post Object
                        (
                            [ID] => 4868
                            [post_author] => 5
                            [post_date] => 2022-06-07 09:30:21
                            [post_date_gmt] => 2022-06-07 09:30:21
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:04:43
                            [post_modified_gmt] => 2022-10-12 11:04:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4868
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [231] => WP_Post Object
                        (
                            [ID] => 4867
                            [post_author] => 5
                            [post_date] => 2022-06-07 09:14:39
                            [post_date_gmt] => 2022-06-07 09:14:39
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-07 09:14:39
                            [post_modified_gmt] => 2022-06-07 09:14:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4867
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [232] => WP_Post Object
                        (
                            [ID] => 4866
                            [post_author] => 5
                            [post_date] => 2022-06-07 08:53:11
                            [post_date_gmt] => 2022-06-07 08:53:11
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-07 08:53:11
                            [post_modified_gmt] => 2022-06-07 08:53:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4866
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [233] => WP_Post Object
                        (
                            [ID] => 4865
                            [post_author] => 5
                            [post_date] => 2022-06-07 08:46:16
                            [post_date_gmt] => 2022-06-07 08:46:16
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-07 08:46:16
                            [post_modified_gmt] => 2022-06-07 08:46:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4865
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [234] => WP_Post Object
                        (
                            [ID] => 4864
                            [post_author] => 5
                            [post_date] => 2022-06-07 08:29:48
                            [post_date_gmt] => 2022-06-07 08:29:48
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:44:52
                            [post_modified_gmt] => 2022-12-14 13:44:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4864
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [235] => WP_Post Object
                        (
                            [ID] => 4863
                            [post_author] => 5
                            [post_date] => 2022-06-06 14:26:47
                            [post_date_gmt] => 2022-06-06 14:26:47
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-06 09:55:41
                            [post_modified_gmt] => 2022-07-06 09:55:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4863
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [236] => WP_Post Object
                        (
                            [ID] => 4862
                            [post_author] => 5
                            [post_date] => 2022-06-06 14:20:32
                            [post_date_gmt] => 2022-06-06 14:20:32
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-06 14:20:32
                            [post_modified_gmt] => 2022-06-06 14:20:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4862
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [237] => WP_Post Object
                        (
                            [ID] => 4861
                            [post_author] => 5
                            [post_date] => 2022-06-06 13:55:49
                            [post_date_gmt] => 2022-06-06 13:55:49
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:43:05
                            [post_modified_gmt] => 2022-09-26 14:43:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4861
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [238] => WP_Post Object
                        (
                            [ID] => 4860
                            [post_author] => 5
                            [post_date] => 2022-06-06 13:12:22
                            [post_date_gmt] => 2022-06-06 13:12:22
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-06 13:12:22
                            [post_modified_gmt] => 2022-06-06 13:12:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4860
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [239] => WP_Post Object
                        (
                            [ID] => 4859
                            [post_author] => 5
                            [post_date] => 2022-06-06 12:38:41
                            [post_date_gmt] => 2022-06-06 12:38:41
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 12:06:45
                            [post_modified_gmt] => 2022-07-13 12:06:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4859
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [240] => WP_Post Object
                        (
                            [ID] => 4858
                            [post_author] => 5
                            [post_date] => 2022-06-02 12:35:22
                            [post_date_gmt] => 2022-06-02 12:35:22
                            [post_content] => 
                            [post_title] => Boston University Startup Exclusive License Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => boston-university-startup-exclusive-license-template
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-02 13:02:59
                            [post_modified_gmt] => 2022-06-02 13:02:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4858
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [241] => WP_Post Object
                        (
                            [ID] => 4857
                            [post_author] => 5
                            [post_date] => 2022-06-02 10:16:52
                            [post_date_gmt] => 2022-06-02 10:16:52
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:06:21
                            [post_modified_gmt] => 2022-10-12 11:06:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4857
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [242] => WP_Post Object
                        (
                            [ID] => 4855
                            [post_author] => 5
                            [post_date] => 2022-06-01 11:59:15
                            [post_date_gmt] => 2022-06-01 11:59:15
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:39:39
                            [post_modified_gmt] => 2022-08-11 09:39:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4855
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [243] => WP_Post Object
                        (
                            [ID] => 4853
                            [post_author] => 5
                            [post_date] => 2022-06-01 11:47:22
                            [post_date_gmt] => 2022-06-01 11:47:22
                            [post_content] => 
                            [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:40:07
                            [post_modified_gmt] => 2022-08-11 09:40:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4853
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [244] => WP_Post Object
                        (
                            [ID] => 4850
                            [post_author] => 5
                            [post_date] => 2022-05-31 10:27:15
                            [post_date_gmt] => 2022-05-31 10:27:15
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:06:38
                            [post_modified_gmt] => 2022-10-12 11:06:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4850
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [245] => WP_Post Object
                        (
                            [ID] => 4849
                            [post_author] => 5
                            [post_date] => 2022-05-31 10:09:48
                            [post_date_gmt] => 2022-05-31 10:09:48
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:51:11
                            [post_modified_gmt] => 2022-09-26 14:51:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4849
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [246] => WP_Post Object
                        (
                            [ID] => 4848
                            [post_author] => 5
                            [post_date] => 2022-05-31 09:49:03
                            [post_date_gmt] => 2022-05-31 09:49:03
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 10:11:26
                            [post_modified_gmt] => 2022-05-31 10:11:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4848
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [247] => WP_Post Object
                        (
                            [ID] => 4847
                            [post_author] => 5
                            [post_date] => 2022-05-31 09:19:59
                            [post_date_gmt] => 2022-05-31 09:19:59
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 09:19:59
                            [post_modified_gmt] => 2022-05-31 09:19:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4847
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [248] => WP_Post Object
                        (
                            [ID] => 4846
                            [post_author] => 5
                            [post_date] => 2022-05-31 09:13:07
                            [post_date_gmt] => 2022-05-31 09:13:07
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 09:13:58
                            [post_modified_gmt] => 2022-05-31 09:13:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4846
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [249] => WP_Post Object
                        (
                            [ID] => 4845
                            [post_author] => 5
                            [post_date] => 2022-05-31 08:57:11
                            [post_date_gmt] => 2022-05-31 08:57:11
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 09:01:01
                            [post_modified_gmt] => 2022-05-31 09:01:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4845
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [250] => WP_Post Object
                        (
                            [ID] => 4844
                            [post_author] => 5
                            [post_date] => 2022-05-31 08:52:57
                            [post_date_gmt] => 2022-05-31 08:52:57
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 08:52:57
                            [post_modified_gmt] => 2022-05-31 08:52:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4844
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [251] => WP_Post Object
                        (
                            [ID] => 4843
                            [post_author] => 5
                            [post_date] => 2022-05-31 08:47:53
                            [post_date_gmt] => 2022-05-31 08:47:53
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:19:47
                            [post_modified_gmt] => 2022-09-29 11:19:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4843
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [252] => WP_Post Object
                        (
                            [ID] => 4842
                            [post_author] => 5
                            [post_date] => 2022-05-31 08:33:58
                            [post_date_gmt] => 2022-05-31 08:33:58
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:45:25
                            [post_modified_gmt] => 2022-12-14 13:45:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4842
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [253] => WP_Post Object
                        (
                            [ID] => 4841
                            [post_author] => 5
                            [post_date] => 2022-05-31 08:22:01
                            [post_date_gmt] => 2022-05-31 08:22:01
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:51:15
                            [post_modified_gmt] => 2022-10-12 12:51:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4841
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [254] => WP_Post Object
                        (
                            [ID] => 4840
                            [post_author] => 5
                            [post_date] => 2022-05-31 08:10:32
                            [post_date_gmt] => 2022-05-31 08:10:32
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-09 12:50:34
                            [post_modified_gmt] => 2022-06-09 12:50:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4840
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [255] => WP_Post Object
                        (
                            [ID] => 4838
                            [post_author] => 5
                            [post_date] => 2022-05-27 15:01:58
                            [post_date_gmt] => 2022-05-27 15:01:58
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-30 09:39:44
                            [post_modified_gmt] => 2022-06-30 09:39:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4838
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [256] => WP_Post Object
                        (
                            [ID] => 4837
                            [post_author] => 5
                            [post_date] => 2022-05-27 14:43:04
                            [post_date_gmt] => 2022-05-27 14:43:04
                            [post_content] => 
                            [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 12:57:32
                            [post_modified_gmt] => 2022-07-13 12:57:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4837
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [257] => WP_Post Object
                        (
                            [ID] => 4835
                            [post_author] => 5
                            [post_date] => 2022-05-27 14:00:10
                            [post_date_gmt] => 2022-05-27 14:00:10
                            [post_content] => 
                            [post_title] => Elkurt - Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 13:14:49
                            [post_modified_gmt] => 2022-10-13 13:14:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4835
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [258] => WP_Post Object
                        (
                            [ID] => 4834
                            [post_author] => 5
                            [post_date] => 2022-05-27 13:26:16
                            [post_date_gmt] => 2022-05-27 13:26:16
                            [post_content] => 
                            [post_title] => Elkurt - Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 09:28:10
                            [post_modified_gmt] => 2022-07-13 09:28:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4834
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [259] => WP_Post Object
                        (
                            [ID] => 4808
                            [post_author] => 5
                            [post_date] => 2022-05-24 09:09:54
                            [post_date_gmt] => 2022-05-24 09:09:54
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:49:36
                            [post_modified_gmt] => 2022-09-26 14:49:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4808
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [260] => WP_Post Object
                        (
                            [ID] => 4807
                            [post_author] => 5
                            [post_date] => 2022-05-24 09:02:55
                            [post_date_gmt] => 2022-05-24 09:02:55
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-24 09:02:55
                            [post_modified_gmt] => 2022-05-24 09:02:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4807
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [261] => WP_Post Object
                        (
                            [ID] => 4806
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:59:08
                            [post_date_gmt] => 2022-05-24 08:59:08
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:11:34
                            [post_modified_gmt] => 2022-10-12 11:11:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4806
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [262] => WP_Post Object
                        (
                            [ID] => 4805
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:53:12
                            [post_date_gmt] => 2022-05-24 08:53:12
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-24 08:59:42
                            [post_modified_gmt] => 2022-05-24 08:59:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4805
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [263] => WP_Post Object
                        (
                            [ID] => 4804
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:40:15
                            [post_date_gmt] => 2022-05-24 08:40:15
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-24 08:53:51
                            [post_modified_gmt] => 2022-05-24 08:53:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4804
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [264] => WP_Post Object
                        (
                            [ID] => 4802
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:24:23
                            [post_date_gmt] => 2022-05-24 08:24:23
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-24 08:24:23
                            [post_modified_gmt] => 2022-05-24 08:24:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4802
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [265] => WP_Post Object
                        (
                            [ID] => 4801
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:19:21
                            [post_date_gmt] => 2022-05-24 08:19:21
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-24 08:19:21
                            [post_modified_gmt] => 2022-05-24 08:19:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4801
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [266] => WP_Post Object
                        (
                            [ID] => 4800
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:07:39
                            [post_date_gmt] => 2022-05-24 08:07:39
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:53:27
                            [post_modified_gmt] => 2022-10-12 12:53:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4800
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [267] => WP_Post Object
                        (
                            [ID] => 4798
                            [post_author] => 5
                            [post_date] => 2022-05-23 14:11:13
                            [post_date_gmt] => 2022-05-23 14:11:13
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:46:09
                            [post_modified_gmt] => 2022-12-14 13:46:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4798
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [268] => WP_Post Object
                        (
                            [ID] => 4797
                            [post_author] => 5
                            [post_date] => 2022-05-23 13:54:57
                            [post_date_gmt] => 2022-05-23 13:54:57
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 12:28:31
                            [post_modified_gmt] => 2022-07-13 12:28:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4797
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [269] => WP_Post Object
                        (
                            [ID] => 4796
                            [post_author] => 5
                            [post_date] => 2022-05-23 13:54:05
                            [post_date_gmt] => 2022-05-23 13:54:05
                            [post_content] => 
                            [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:32:56
                            [post_modified_gmt] => 2022-12-15 16:32:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4796
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [270] => WP_Post Object
                        (
                            [ID] => 4704
                            [post_author] => 5
                            [post_date] => 2022-04-26 15:08:03
                            [post_date_gmt] => 2022-04-26 15:08:03
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:12:02
                            [post_modified_gmt] => 2022-10-12 11:12:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4704
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [271] => WP_Post Object
                        (
                            [ID] => 4703
                            [post_author] => 5
                            [post_date] => 2022-04-26 14:56:55
                            [post_date_gmt] => 2022-04-26 14:56:55
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:42:15
                            [post_modified_gmt] => 2022-08-11 09:42:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4703
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [272] => WP_Post Object
                        (
                            [ID] => 4702
                            [post_author] => 5
                            [post_date] => 2022-04-26 14:46:00
                            [post_date_gmt] => 2022-04-26 14:46:00
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:54:09
                            [post_modified_gmt] => 2023-01-04 15:54:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4702
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [273] => WP_Post Object
                        (
                            [ID] => 4701
                            [post_author] => 5
                            [post_date] => 2022-04-26 14:30:45
                            [post_date_gmt] => 2022-04-26 14:30:45
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:43:48
                            [post_modified_gmt] => 2022-08-11 09:43:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4701
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [274] => WP_Post Object
                        (
                            [ID] => 4700
                            [post_author] => 5
                            [post_date] => 2022-04-26 14:23:46
                            [post_date_gmt] => 2022-04-26 14:23:46
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:26:36
                            [post_modified_gmt] => 2022-09-29 11:26:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4700
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [275] => WP_Post Object
                        (
                            [ID] => 4699
                            [post_author] => 5
                            [post_date] => 2022-04-26 14:06:18
                            [post_date_gmt] => 2022-04-26 14:06:18
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:39:26
                            [post_modified_gmt] => 2022-09-26 14:39:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4699
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [276] => WP_Post Object
                        (
                            [ID] => 4698
                            [post_author] => 5
                            [post_date] => 2022-04-26 12:27:58
                            [post_date_gmt] => 2022-04-26 12:27:58
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:54:04
                            [post_modified_gmt] => 2022-10-12 12:54:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4698
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [277] => WP_Post Object
                        (
                            [ID] => 4697
                            [post_author] => 5
                            [post_date] => 2022-04-26 12:05:54
                            [post_date_gmt] => 2022-04-26 12:05:54
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:44:46
                            [post_modified_gmt] => 2022-08-11 09:44:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4697
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [278] => WP_Post Object
                        (
                            [ID] => 4696
                            [post_author] => 5
                            [post_date] => 2022-04-26 11:05:38
                            [post_date_gmt] => 2022-04-26 11:05:38
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:45:08
                            [post_modified_gmt] => 2022-08-11 09:45:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4696
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [279] => WP_Post Object
                        (
                            [ID] => 4695
                            [post_author] => 5
                            [post_date] => 2022-04-26 09:54:07
                            [post_date_gmt] => 2022-04-26 09:54:07
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-24 13:04:06
                            [post_modified_gmt] => 2023-01-24 13:04:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4695
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [280] => WP_Post Object
                        (
                            [ID] => 4691
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:59:51
                            [post_date_gmt] => 2022-04-25 12:59:51
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:37:35
                            [post_modified_gmt] => 2022-09-26 14:37:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4691
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [281] => WP_Post Object
                        (
                            [ID] => 4690
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:53:48
                            [post_date_gmt] => 2022-04-25 12:53:48
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:46:23
                            [post_modified_gmt] => 2022-08-11 09:46:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4690
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [282] => WP_Post Object
                        (
                            [ID] => 4689
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:48:26
                            [post_date_gmt] => 2022-04-25 12:48:26
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:46:36
                            [post_modified_gmt] => 2022-08-11 09:46:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4689
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [283] => WP_Post Object
                        (
                            [ID] => 4688
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:44:13
                            [post_date_gmt] => 2022-04-25 12:44:13
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:46:53
                            [post_modified_gmt] => 2022-08-11 09:46:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4688
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [284] => WP_Post Object
                        (
                            [ID] => 4687
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:41:22
                            [post_date_gmt] => 2022-04-25 12:41:22
                            [post_content] => 
                            [post_title] => Gates Foundation - Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:47:22
                            [post_modified_gmt] => 2022-08-11 09:47:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4687
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [285] => WP_Post Object
                        (
                            [ID] => 4686
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:37:16
                            [post_date_gmt] => 2022-04-25 12:37:16
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:47:39
                            [post_modified_gmt] => 2022-08-11 09:47:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4686
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [286] => WP_Post Object
                        (
                            [ID] => 4685
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:29:54
                            [post_date_gmt] => 2022-04-25 12:29:54
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => what-are-the-mechanisms-to-limit-exposure-to-additional-payments-or-expenses
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:26:17
                            [post_modified_gmt] => 2022-09-29 11:26:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4685
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [287] => WP_Post Object
                        (
                            [ID] => 4684
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:25:07
                            [post_date_gmt] => 2022-04-25 12:25:07
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:46:43
                            [post_modified_gmt] => 2022-12-14 13:46:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4684
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [288] => WP_Post Object
                        (
                            [ID] => 4683
                            [post_author] => 5
                            [post_date] => 2022-04-25 12:03:48
                            [post_date_gmt] => 2022-04-25 12:03:48
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-23 09:59:14
                            [post_modified_gmt] => 2022-08-23 09:59:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4683
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [289] => WP_Post Object
                        (
                            [ID] => 4682
                            [post_author] => 5
                            [post_date] => 2022-04-25 11:56:46
                            [post_date_gmt] => 2022-04-25 11:56:46
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:54:40
                            [post_modified_gmt] => 2022-10-12 12:54:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4682
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [290] => WP_Post Object
                        (
                            [ID] => 4681
                            [post_author] => 5
                            [post_date] => 2022-04-25 11:39:24
                            [post_date_gmt] => 2022-04-25 11:39:24
                            [post_content] => 
                            [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-24 12:50:38
                            [post_modified_gmt] => 2023-01-24 12:50:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4681
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [291] => WP_Post Object
                        (
                            [ID] => 4680
                            [post_author] => 5
                            [post_date] => 2022-04-25 11:17:54
                            [post_date_gmt] => 2022-04-25 11:17:54
                            [post_content] => 
                            [post_title] => Gates Foundation - Arsanis RSV Monoclonal Antibodies Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:52:04
                            [post_modified_gmt] => 2022-08-11 09:52:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4680
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [292] => WP_Post Object
                        (
                            [ID] => 4661
                            [post_author] => 5
                            [post_date] => 2022-04-20 08:13:06
                            [post_date_gmt] => 2022-04-20 08:13:06
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:53:17
                            [post_modified_gmt] => 2022-10-03 13:53:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4661
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [293] => WP_Post Object
                        (
                            [ID] => 4147
                            [post_author] => 5
                            [post_date] => 2022-04-18 12:53:51
                            [post_date_gmt] => 2022-04-18 12:53:51
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:24:43
                            [post_modified_gmt] => 2022-12-15 16:24:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4147
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [294] => WP_Post Object
                        (
                            [ID] => 4601
                            [post_author] => 5
                            [post_date] => 2022-04-18 10:40:48
                            [post_date_gmt] => 2022-04-18 10:40:48
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 10:44:46
                            [post_modified_gmt] => 2022-04-18 10:44:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4601
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [295] => WP_Post Object
                        (
                            [ID] => 4148
                            [post_author] => 5
                            [post_date] => 2022-04-12 08:59:45
                            [post_date_gmt] => 2022-04-12 08:59:45
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-04 09:32:39
                            [post_modified_gmt] => 2022-10-04 09:32:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4148
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [296] => WP_Post Object
                        (
                            [ID] => 4580
                            [post_author] => 5
                            [post_date] => 2022-03-31 14:34:38
                            [post_date_gmt] => 2022-03-31 14:34:38
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-05 14:02:54
                            [post_modified_gmt] => 2023-01-05 14:02:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4580
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [297] => WP_Post Object
                        (
                            [ID] => 4519
                            [post_author] => 5
                            [post_date] => 2022-03-25 12:48:09
                            [post_date_gmt] => 2022-03-25 12:48:09
                            [post_content] => 
                            [post_title] => Gates Foundation Sample Grant Terms & Conditions
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-sample-grant-terms-conditions
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:25:09
                            [post_modified_gmt] => 2022-12-15 16:25:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4519
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [298] => WP_Post Object
                        (
                            [ID] => 4516
                            [post_author] => 5
                            [post_date] => 2022-03-23 09:07:57
                            [post_date_gmt] => 2022-03-23 09:07:57
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-20 08:36:12
                            [post_modified_gmt] => 2022-09-20 08:36:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4516
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [299] => WP_Post Object
                        (
                            [ID] => 4491
                            [post_author] => 5
                            [post_date] => 2022-03-17 15:42:04
                            [post_date_gmt] => 2022-03-17 15:42:04
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-03-17 15:42:04
                            [post_modified_gmt] => 2022-03-17 15:42:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4491
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [300] => WP_Post Object
                        (
                            [ID] => 4490
                            [post_author] => 5
                            [post_date] => 2022-03-17 15:37:26
                            [post_date_gmt] => 2022-03-17 15:37:26
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:12:35
                            [post_modified_gmt] => 2022-10-12 11:12:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4490
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [301] => WP_Post Object
                        (
                            [ID] => 4489
                            [post_author] => 5
                            [post_date] => 2022-03-17 15:33:45
                            [post_date_gmt] => 2022-03-17 15:33:45
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:44:40
                            [post_modified_gmt] => 2022-09-26 14:44:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4489
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [302] => WP_Post Object
                        (
                            [ID] => 4488
                            [post_author] => 5
                            [post_date] => 2022-03-17 15:11:54
                            [post_date_gmt] => 2022-03-17 15:11:54
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-23 10:48:00
                            [post_modified_gmt] => 2022-05-23 10:48:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4488
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [303] => WP_Post Object
                        (
                            [ID] => 4487
                            [post_author] => 5
                            [post_date] => 2022-03-17 14:58:23
                            [post_date_gmt] => 2022-03-17 14:58:23
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-03-17 15:04:54
                            [post_modified_gmt] => 2022-03-17 15:04:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4487
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [304] => WP_Post Object
                        (
                            [ID] => 4486
                            [post_author] => 5
                            [post_date] => 2022-03-17 14:50:08
                            [post_date_gmt] => 2022-03-17 14:50:08
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-03-17 14:50:08
                            [post_modified_gmt] => 2022-03-17 14:50:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4486
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [305] => WP_Post Object
                        (
                            [ID] => 4485
                            [post_author] => 5
                            [post_date] => 2022-03-17 14:43:27
                            [post_date_gmt] => 2022-03-17 14:43:27
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-03-17 15:04:43
                            [post_modified_gmt] => 2022-03-17 15:04:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4485
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [306] => WP_Post Object
                        (
                            [ID] => 4484
                            [post_author] => 5
                            [post_date] => 2022-03-17 13:56:19
                            [post_date_gmt] => 2022-03-17 13:56:19
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 10:50:14
                            [post_modified_gmt] => 2022-09-29 10:50:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4484
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [307] => WP_Post Object
                        (
                            [ID] => 4483
                            [post_author] => 5
                            [post_date] => 2022-03-17 13:21:19
                            [post_date_gmt] => 2022-03-17 13:21:19
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-03-17 13:22:33
                            [post_modified_gmt] => 2022-03-17 13:22:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4483
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [308] => WP_Post Object
                        (
                            [ID] => 4482
                            [post_author] => 5
                            [post_date] => 2022-03-17 12:43:13
                            [post_date_gmt] => 2022-03-17 12:43:13
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:55:30
                            [post_modified_gmt] => 2022-10-12 12:55:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4482
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [309] => WP_Post Object
                        (
                            [ID] => 4481
                            [post_author] => 5
                            [post_date] => 2022-03-17 12:28:49
                            [post_date_gmt] => 2022-03-17 12:28:49
                            [post_content] => 
                            [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 12:08:00
                            [post_modified_gmt] => 2022-07-13 12:08:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4481
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [310] => WP_Post Object
                        (
                            [ID] => 4469
                            [post_author] => 5
                            [post_date] => 2022-03-17 10:55:42
                            [post_date_gmt] => 2022-03-17 10:55:42
                            [post_content] => 
                            [post_title] => Cellscript - BioNTech mRNA Technology Patent Sublicense
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cellscript-biontech-mrna-technology-patent-sublicense
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 13:16:32
                            [post_modified_gmt] => 2022-10-13 13:16:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4469
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [311] => WP_Post Object
                        (
                            [ID] => 4223
                            [post_author] => 5
                            [post_date] => 2022-03-04 09:43:58
                            [post_date_gmt] => 2022-03-04 09:43:58
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 18:00:18
                            [post_modified_gmt] => 2022-05-31 18:00:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4223
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [312] => WP_Post Object
                        (
                            [ID] => 4222
                            [post_author] => 5
                            [post_date] => 2022-03-04 09:14:41
                            [post_date_gmt] => 2022-03-04 09:14:41
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:13:06
                            [post_modified_gmt] => 2022-10-12 11:13:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4222
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [313] => WP_Post Object
                        (
                            [ID] => 4221
                            [post_author] => 5
                            [post_date] => 2022-03-04 09:05:29
                            [post_date_gmt] => 2022-03-04 09:05:29
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:36:15
                            [post_modified_gmt] => 2022-09-26 14:36:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4221
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [314] => WP_Post Object
                        (
                            [ID] => 4220
                            [post_author] => 5
                            [post_date] => 2022-03-04 08:47:04
                            [post_date_gmt] => 2022-03-04 08:47:04
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 15:08:10
                            [post_modified_gmt] => 2022-05-31 15:08:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4220
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [315] => WP_Post Object
                        (
                            [ID] => 4219
                            [post_author] => 5
                            [post_date] => 2022-03-04 08:02:15
                            [post_date_gmt] => 2022-03-04 08:02:15
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:55:41
                            [post_modified_gmt] => 2023-01-04 15:55:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4219
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [316] => WP_Post Object
                        (
                            [ID] => 4218
                            [post_author] => 5
                            [post_date] => 2022-03-03 14:17:53
                            [post_date_gmt] => 2022-03-03 14:17:53
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:10:14
                            [post_modified_gmt] => 2023-01-04 15:10:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4218
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [317] => WP_Post Object
                        (
                            [ID] => 4217
                            [post_author] => 5
                            [post_date] => 2022-03-03 13:59:58
                            [post_date_gmt] => 2022-03-03 13:59:58
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 17:56:43
                            [post_modified_gmt] => 2022-05-31 17:56:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4217
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [318] => WP_Post Object
                        (
                            [ID] => 4216
                            [post_author] => 5
                            [post_date] => 2022-03-03 13:45:21
                            [post_date_gmt] => 2022-03-03 13:45:21
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 17:56:00
                            [post_modified_gmt] => 2022-05-31 17:56:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4216
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [319] => WP_Post Object
                        (
                            [ID] => 4215
                            [post_author] => 5
                            [post_date] => 2022-03-03 13:31:56
                            [post_date_gmt] => 2022-03-03 13:31:56
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 10:41:55
                            [post_modified_gmt] => 2022-09-29 10:41:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4215
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [320] => WP_Post Object
                        (
                            [ID] => 4214
                            [post_author] => 5
                            [post_date] => 2022-03-03 12:54:33
                            [post_date_gmt] => 2022-03-03 12:54:33
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:33:50
                            [post_modified_gmt] => 2022-12-15 16:33:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4214
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [321] => WP_Post Object
                        (
                            [ID] => 4213
                            [post_author] => 5
                            [post_date] => 2022-03-03 10:54:01
                            [post_date_gmt] => 2022-03-03 10:54:01
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-05-31 15:05:32
                            [post_modified_gmt] => 2022-05-31 15:05:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4213
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [322] => WP_Post Object
                        (
                            [ID] => 4212
                            [post_author] => 5
                            [post_date] => 2022-03-02 14:54:16
                            [post_date_gmt] => 2022-03-02 14:54:16
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:56:25
                            [post_modified_gmt] => 2022-10-12 12:56:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4212
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [323] => WP_Post Object
                        (
                            [ID] => 4210
                            [post_author] => 5
                            [post_date] => 2022-03-02 13:14:31
                            [post_date_gmt] => 2022-03-02 13:14:31
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 12:03:49
                            [post_modified_gmt] => 2022-07-13 12:03:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4210
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [324] => WP_Post Object
                        (
                            [ID] => 4209
                            [post_author] => 5
                            [post_date] => 2022-03-02 12:07:13
                            [post_date_gmt] => 2022-03-02 12:07:13
                            [post_content] => 
                            [post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 13:16:54
                            [post_modified_gmt] => 2022-10-13 13:16:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4209
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [325] => WP_Post Object
                        (
                            [ID] => 4205
                            [post_author] => 5
                            [post_date] => 2022-02-28 15:24:19
                            [post_date_gmt] => 2022-02-28 15:24:19
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:59:13
                            [post_modified_gmt] => 2022-10-12 12:59:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4205
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [326] => WP_Post Object
                        (
                            [ID] => 4204
                            [post_author] => 5
                            [post_date] => 2022-02-28 14:53:11
                            [post_date_gmt] => 2022-02-28 14:53:11
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:07:32
                            [post_modified_gmt] => 2022-12-14 13:07:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4204
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [327] => WP_Post Object
                        (
                            [ID] => 4201
                            [post_author] => 5
                            [post_date] => 2022-02-28 13:33:22
                            [post_date_gmt] => 2022-02-28 13:33:22
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 13:13:57
                            [post_modified_gmt] => 2023-01-10 13:13:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4201
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [328] => WP_Post Object
                        (
                            [ID] => 4200
                            [post_author] => 5
                            [post_date] => 2022-02-28 13:13:29
                            [post_date_gmt] => 2022-02-28 13:13:29
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:13:52
                            [post_modified_gmt] => 2022-10-12 11:13:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4200
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [329] => WP_Post Object
                        (
                            [ID] => 4161
                            [post_author] => 5
                            [post_date] => 2022-02-02 13:48:58
                            [post_date_gmt] => 2022-02-02 13:48:58
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 09:53:28
                            [post_modified_gmt] => 2022-12-15 09:53:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4161
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [330] => WP_Post Object
                        (
                            [ID] => 4159
                            [post_author] => 5
                            [post_date] => 2022-02-02 13:10:48
                            [post_date_gmt] => 2022-02-02 13:10:48
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:15:11
                            [post_modified_gmt] => 2022-10-12 11:15:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4159
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [331] => WP_Post Object
                        (
                            [ID] => 4158
                            [post_author] => 5
                            [post_date] => 2022-02-02 13:00:08
                            [post_date_gmt] => 2022-02-02 13:00:08
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 12:48:45
                            [post_modified_gmt] => 2023-01-03 12:48:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4158
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [332] => WP_Post Object
                        (
                            [ID] => 4157
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:54:56
                            [post_date_gmt] => 2022-02-02 12:54:56
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:13:37
                            [post_modified_gmt] => 2022-04-18 13:13:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4157
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [333] => WP_Post Object
                        (
                            [ID] => 4156
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:36:42
                            [post_date_gmt] => 2022-02-02 12:36:42
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:10:37
                            [post_modified_gmt] => 2023-01-04 15:10:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4156
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [334] => WP_Post Object
                        (
                            [ID] => 4155
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:19:16
                            [post_date_gmt] => 2022-02-02 12:19:16
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:12:26
                            [post_modified_gmt] => 2022-04-18 13:12:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4155
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [335] => WP_Post Object
                        (
                            [ID] => 4154
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:13:41
                            [post_date_gmt] => 2022-02-02 12:13:41
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-02-02 12:13:41
                            [post_modified_gmt] => 2022-02-02 12:13:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4154
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [336] => WP_Post Object
                        (
                            [ID] => 4153
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:10:13
                            [post_date_gmt] => 2022-02-02 12:10:13
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:28:28
                            [post_modified_gmt] => 2022-09-29 11:28:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4153
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [337] => WP_Post Object
                        (
                            [ID] => 4152
                            [post_author] => 5
                            [post_date] => 2022-02-02 11:51:54
                            [post_date_gmt] => 2022-02-02 11:51:54
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:57:07
                            [post_modified_gmt] => 2022-09-26 14:57:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4152
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [338] => WP_Post Object
                        (
                            [ID] => 4151
                            [post_author] => 5
                            [post_date] => 2022-02-02 11:39:24
                            [post_date_gmt] => 2022-02-02 11:39:24
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:00:22
                            [post_modified_gmt] => 2022-10-12 13:00:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4151
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [339] => WP_Post Object
                        (
                            [ID] => 4150
                            [post_author] => 5
                            [post_date] => 2022-02-02 10:24:30
                            [post_date_gmt] => 2022-02-02 10:24:30
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 13:01:03
                            [post_modified_gmt] => 2022-04-18 13:01:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4150
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [340] => WP_Post Object
                        (
                            [ID] => 4149
                            [post_author] => 5
                            [post_date] => 2022-02-02 10:15:42
                            [post_date_gmt] => 2022-02-02 10:15:42
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:35:19
                            [post_modified_gmt] => 2022-12-15 16:35:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4149
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [341] => WP_Post Object
                        (
                            [ID] => 4146
                            [post_author] => 5
                            [post_date] => 2022-02-02 07:28:42
                            [post_date_gmt] => 2022-02-02 07:28:42
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 13:18:01
                            [post_modified_gmt] => 2022-10-13 13:18:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4146
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [342] => WP_Post Object
                        (
                            [ID] => 4141
                            [post_author] => 5
                            [post_date] => 2022-01-31 14:31:23
                            [post_date_gmt] => 2022-01-31 14:31:23
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:40:20
                            [post_modified_gmt] => 2023-01-10 10:40:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4141
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [343] => WP_Post Object
                        (
                            [ID] => 4140
                            [post_author] => 5
                            [post_date] => 2022-01-31 14:22:03
                            [post_date_gmt] => 2022-01-31 14:22:03
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:54:15
                            [post_modified_gmt] => 2023-01-10 10:54:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4140
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [344] => WP_Post Object
                        (
                            [ID] => 4139
                            [post_author] => 5
                            [post_date] => 2022-01-31 14:18:32
                            [post_date_gmt] => 2022-01-31 14:18:32
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:58:00
                            [post_modified_gmt] => 2023-01-10 10:58:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4139
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [345] => WP_Post Object
                        (
                            [ID] => 4138
                            [post_author] => 5
                            [post_date] => 2022-01-31 14:09:33
                            [post_date_gmt] => 2022-01-31 14:09:33
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:59:39
                            [post_modified_gmt] => 2023-01-10 10:59:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4138
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [346] => WP_Post Object
                        (
                            [ID] => 4137
                            [post_author] => 5
                            [post_date] => 2022-01-31 13:53:37
                            [post_date_gmt] => 2022-01-31 13:53:37
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 11:02:20
                            [post_modified_gmt] => 2023-01-10 11:02:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4137
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [347] => WP_Post Object
                        (
                            [ID] => 4136
                            [post_author] => 5
                            [post_date] => 2022-01-31 13:42:47
                            [post_date_gmt] => 2022-01-31 13:42:47
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 11:01:51
                            [post_modified_gmt] => 2023-01-10 11:01:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4136
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [348] => WP_Post Object
                        (
                            [ID] => 4135
                            [post_author] => 5
                            [post_date] => 2022-01-31 13:25:08
                            [post_date_gmt] => 2022-01-31 13:25:08
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:59:11
                            [post_modified_gmt] => 2023-01-10 10:59:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4135
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [349] => WP_Post Object
                        (
                            [ID] => 4134
                            [post_author] => 5
                            [post_date] => 2022-01-31 12:56:28
                            [post_date_gmt] => 2022-01-31 12:56:28
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:58:24
                            [post_modified_gmt] => 2023-01-10 10:58:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4134
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [350] => WP_Post Object
                        (
                            [ID] => 4133
                            [post_author] => 5
                            [post_date] => 2022-01-31 12:22:56
                            [post_date_gmt] => 2022-01-31 12:22:56
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:56:11
                            [post_modified_gmt] => 2023-01-10 10:56:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4133
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [351] => WP_Post Object
                        (
                            [ID] => 4131
                            [post_author] => 5
                            [post_date] => 2022-01-29 16:21:19
                            [post_date_gmt] => 2022-01-29 16:21:19
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:56:47
                            [post_modified_gmt] => 2023-01-10 10:56:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4131
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [352] => WP_Post Object
                        (
                            [ID] => 4130
                            [post_author] => 5
                            [post_date] => 2022-01-29 15:34:50
                            [post_date_gmt] => 2022-01-29 15:34:50
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:57:20
                            [post_modified_gmt] => 2023-01-10 10:57:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4130
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [353] => WP_Post Object
                        (
                            [ID] => 4129
                            [post_author] => 5
                            [post_date] => 2022-01-28 14:43:06
                            [post_date_gmt] => 2022-01-28 14:43:06
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 10:53:31
                            [post_modified_gmt] => 2023-01-10 10:53:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4129
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [354] => WP_Post Object
                        (
                            [ID] => 4128
                            [post_author] => 5
                            [post_date] => 2022-01-28 13:38:44
                            [post_date_gmt] => 2022-01-28 13:38:44
                            [post_content] => 
                            [post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 11:07:15
                            [post_modified_gmt] => 2023-01-10 11:07:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4128
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [355] => WP_Post Object
                        (
                            [ID] => 4113
                            [post_author] => 5
                            [post_date] => 2022-01-19 09:21:03
                            [post_date_gmt] => 2022-01-19 09:21:03
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-model-inter-institutional-research-collaboration-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:32:06
                            [post_modified_gmt] => 2022-09-26 14:32:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4113
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [356] => WP_Post Object
                        (
                            [ID] => 4112
                            [post_author] => 5
                            [post_date] => 2022-01-18 14:43:23
                            [post_date_gmt] => 2022-01-18 14:43:23
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-model-inter-institutional-research-collaboration-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-19 09:17:01
                            [post_modified_gmt] => 2022-01-19 09:17:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4112
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [357] => WP_Post Object
                        (
                            [ID] => 4105
                            [post_author] => 5
                            [post_date] => 2022-01-18 13:30:40
                            [post_date_gmt] => 2022-01-18 13:30:40
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-model-inter-institutional-research-collaboration-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:08:20
                            [post_modified_gmt] => 2022-12-14 13:08:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4105
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [358] => WP_Post Object
                        (
                            [ID] => 4098
                            [post_author] => 5
                            [post_date] => 2022-01-12 14:27:12
                            [post_date_gmt] => 2022-01-12 14:27:12
                            [post_content] => 
                            [post_title] => Academic Institution – Company, Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => academic-institution-company-research-collaboration-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-12 14:27:12
                            [post_modified_gmt] => 2022-01-12 14:27:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4098
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [359] => WP_Post Object
                        (
                            [ID] => 4095
                            [post_author] => 5
                            [post_date] => 2022-01-12 13:39:41
                            [post_date_gmt] => 2022-01-12 13:39:41
                            [post_content] => 
                            [post_title] => Academic Institution – Company, Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => academic-institution-company-research-collaboration-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 10:38:01
                            [post_modified_gmt] => 2022-09-29 10:38:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4095
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [360] => WP_Post Object
                        (
                            [ID] => 4094
                            [post_author] => 5
                            [post_date] => 2022-01-12 13:19:48
                            [post_date_gmt] => 2022-01-12 13:19:48
                            [post_content] => 
                            [post_title] => Academic Institution – Company, Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => academic-institution-company-research-collaboration-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-12 13:21:25
                            [post_modified_gmt] => 2022-01-12 13:21:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4094
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [361] => WP_Post Object
                        (
                            [ID] => 4093
                            [post_author] => 5
                            [post_date] => 2022-01-12 13:01:38
                            [post_date_gmt] => 2022-01-12 13:01:38
                            [post_content] => 
                            [post_title] => Academic Institution - Company, Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => academic-institution-company-research-collaboration-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 13:36:58
                            [post_modified_gmt] => 2022-07-13 13:36:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4093
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [362] => WP_Post Object
                        (
                            [ID] => 4092
                            [post_author] => 5
                            [post_date] => 2022-01-12 12:33:49
                            [post_date_gmt] => 2022-01-12 12:33:49
                            [post_content] => 
                            [post_title] => Academic Institution - Company, Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => academic-institution-company-research-collaboration-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 13:18:26
                            [post_modified_gmt] => 2022-10-13 13:18:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4092
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [363] => WP_Post Object
                        (
                            [ID] => 4090
                            [post_author] => 5
                            [post_date] => 2022-01-12 11:48:32
                            [post_date_gmt] => 2022-01-12 11:48:32
                            [post_content] => 
                            [post_title] => Academic Institution - Company, Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => academic-institution-company-research-collaboration-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:17:45
                            [post_modified_gmt] => 2022-10-12 11:17:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4090
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [364] => WP_Post Object
                        (
                            [ID] => 4089
                            [post_author] => 5
                            [post_date] => 2022-01-11 13:35:45
                            [post_date_gmt] => 2022-01-11 13:35:45
                            [post_content] => 
                            [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 14:13:27
                            [post_modified_gmt] => 2022-12-15 14:13:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4089
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [365] => WP_Post Object
                        (
                            [ID] => 4086
                            [post_author] => 5
                            [post_date] => 2022-01-11 12:13:55
                            [post_date_gmt] => 2022-01-11 12:13:55
                            [post_content] => 
                            [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:58:11
                            [post_modified_gmt] => 2023-01-04 15:58:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4086
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [366] => WP_Post Object
                        (
                            [ID] => 4085
                            [post_author] => 5
                            [post_date] => 2022-01-11 12:01:14
                            [post_date_gmt] => 2022-01-11 12:01:14
                            [post_content] => 
                            [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-11 12:01:14
                            [post_modified_gmt] => 2022-01-11 12:01:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4085
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [367] => WP_Post Object
                        (
                            [ID] => 4082
                            [post_author] => 5
                            [post_date] => 2022-01-11 09:06:56
                            [post_date_gmt] => 2022-01-11 09:06:56
                            [post_content] => 
                            [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-11 09:07:31
                            [post_modified_gmt] => 2022-01-11 09:07:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4082
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [368] => WP_Post Object
                        (
                            [ID] => 4081
                            [post_author] => 5
                            [post_date] => 2022-01-11 08:42:56
                            [post_date_gmt] => 2022-01-11 08:42:56
                            [post_content] => 
                            [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:31:24
                            [post_modified_gmt] => 2022-09-29 12:31:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4081
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [369] => WP_Post Object
                        (
                            [ID] => 4080
                            [post_author] => 5
                            [post_date] => 2022-01-11 08:32:58
                            [post_date_gmt] => 2022-01-11 08:32:58
                            [post_content] => 
                            [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-11 15:17:30
                            [post_modified_gmt] => 2022-01-11 15:17:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4080
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [370] => WP_Post Object
                        (
                            [ID] => 4079
                            [post_author] => 5
                            [post_date] => 2022-01-11 08:07:49
                            [post_date_gmt] => 2022-01-11 08:07:49
                            [post_content] => 
                            [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:18:35
                            [post_modified_gmt] => 2022-10-12 11:18:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4079
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [371] => WP_Post Object
                        (
                            [ID] => 4078
                            [post_author] => 5
                            [post_date] => 2022-01-11 07:42:00
                            [post_date_gmt] => 2022-01-11 07:42:00
                            [post_content] => 
                            [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:01:56
                            [post_modified_gmt] => 2022-10-12 13:01:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4078
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [372] => WP_Post Object
                        (
                            [ID] => 4077
                            [post_author] => 5
                            [post_date] => 2022-01-11 07:20:11
                            [post_date_gmt] => 2022-01-11 07:20:11
                            [post_content] => 
                            [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:26:47
                            [post_modified_gmt] => 2022-12-15 16:26:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4077
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [373] => WP_Post Object
                        (
                            [ID] => 4075
                            [post_author] => 5
                            [post_date] => 2022-01-11 05:59:46
                            [post_date_gmt] => 2022-01-11 05:59:46
                            [post_content] => 
                            [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 13:52:33
                            [post_modified_gmt] => 2022-07-13 13:52:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4075
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [374] => WP_Post Object
                        (
                            [ID] => 4072
                            [post_author] => 5
                            [post_date] => 2022-01-08 13:16:04
                            [post_date_gmt] => 2022-01-08 13:16:04
                            [post_content] => 
                            [post_title] => University of Washington - Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 13:19:15
                            [post_modified_gmt] => 2022-10-13 13:19:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4072
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [375] => WP_Post Object
                        (
                            [ID] => 4066
                            [post_author] => 5
                            [post_date] => 2022-01-07 11:35:15
                            [post_date_gmt] => 2022-01-07 11:35:15
                            [post_content] => 
                            [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 13:30:48
                            [post_modified_gmt] => 2022-12-16 13:30:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4066
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [376] => WP_Post Object
                        (
                            [ID] => 4065
                            [post_author] => 5
                            [post_date] => 2022-01-07 11:21:06
                            [post_date_gmt] => 2022-01-07 11:21:06
                            [post_content] => 
                            [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-07 11:21:06
                            [post_modified_gmt] => 2022-01-07 11:21:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4065
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [377] => WP_Post Object
                        (
                            [ID] => 4064
                            [post_author] => 5
                            [post_date] => 2022-01-07 10:57:29
                            [post_date_gmt] => 2022-01-07 10:57:29
                            [post_content] => 
                            [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-07 10:57:29
                            [post_modified_gmt] => 2022-01-07 10:57:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4064
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [378] => WP_Post Object
                        (
                            [ID] => 4063
                            [post_author] => 5
                            [post_date] => 2022-01-07 10:34:51
                            [post_date_gmt] => 2022-01-07 10:34:51
                            [post_content] => 
                            [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 15:43:22
                            [post_modified_gmt] => 2022-12-14 15:43:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4063
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [379] => WP_Post Object
                        (
                            [ID] => 4062
                            [post_author] => 5
                            [post_date] => 2022-01-07 10:03:12
                            [post_date_gmt] => 2022-01-07 10:03:12
                            [post_content] => 
                            [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:30:30
                            [post_modified_gmt] => 2022-09-26 14:30:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4062
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [380] => WP_Post Object
                        (
                            [ID] => 4061
                            [post_author] => 5
                            [post_date] => 2022-01-07 09:46:42
                            [post_date_gmt] => 2022-01-07 09:46:42
                            [post_content] => 
                            [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:19:10
                            [post_modified_gmt] => 2022-10-12 11:19:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4061
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [381] => WP_Post Object
                        (
                            [ID] => 4060
                            [post_author] => 5
                            [post_date] => 2022-01-07 09:40:49
                            [post_date_gmt] => 2022-01-07 09:40:49
                            [post_content] => 
                            [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => path-aridis-rotavirus-vaccine-development-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:27:06
                            [post_modified_gmt] => 2022-12-15 16:27:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4060
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [382] => WP_Post Object
                        (
                            [ID] => 4058
                            [post_author] => 5
                            [post_date] => 2022-01-04 14:25:52
                            [post_date_gmt] => 2022-01-04 14:25:52
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 12:47:11
                            [post_modified_gmt] => 2023-01-03 12:47:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4058
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [383] => WP_Post Object
                        (
                            [ID] => 4054
                            [post_author] => 5
                            [post_date] => 2022-01-03 11:45:52
                            [post_date_gmt] => 2022-01-03 11:45:52
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 14:45:07
                            [post_modified_gmt] => 2022-12-15 14:45:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4054
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [384] => WP_Post Object
                        (
                            [ID] => 4051
                            [post_author] => 5
                            [post_date] => 2022-01-03 11:01:41
                            [post_date_gmt] => 2022-01-03 11:01:41
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:19:50
                            [post_modified_gmt] => 2022-10-12 11:19:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4051
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [385] => WP_Post Object
                        (
                            [ID] => 4050
                            [post_author] => 5
                            [post_date] => 2022-01-03 10:49:32
                            [post_date_gmt] => 2022-01-03 10:49:32
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-03 10:56:55
                            [post_modified_gmt] => 2022-01-03 10:56:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4050
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [386] => WP_Post Object
                        (
                            [ID] => 4047
                            [post_author] => 5
                            [post_date] => 2021-12-27 17:17:36
                            [post_date_gmt] => 2021-12-27 17:17:36
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 16:05:43
                            [post_modified_gmt] => 2023-01-04 16:05:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4047
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [387] => WP_Post Object
                        (
                            [ID] => 4046
                            [post_author] => 5
                            [post_date] => 2021-12-27 17:10:47
                            [post_date_gmt] => 2021-12-27 17:10:47
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:13:16
                            [post_modified_gmt] => 2023-01-04 15:13:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4046
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [388] => WP_Post Object
                        (
                            [ID] => 4045
                            [post_author] => 5
                            [post_date] => 2021-12-27 17:07:25
                            [post_date_gmt] => 2021-12-27 17:07:25
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-12-27 17:07:25
                            [post_modified_gmt] => 2021-12-27 17:07:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4045
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [389] => WP_Post Object
                        (
                            [ID] => 4043
                            [post_author] => 5
                            [post_date] => 2021-12-27 16:47:54
                            [post_date_gmt] => 2021-12-27 16:47:54
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-12-27 16:47:54
                            [post_modified_gmt] => 2021-12-27 16:47:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4043
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [390] => WP_Post Object
                        (
                            [ID] => 4042
                            [post_author] => 5
                            [post_date] => 2021-12-27 16:41:56
                            [post_date_gmt] => 2021-12-27 16:41:56
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:25:56
                            [post_modified_gmt] => 2022-09-29 12:25:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4042
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [391] => WP_Post Object
                        (
                            [ID] => 4041
                            [post_author] => 5
                            [post_date] => 2021-12-27 16:28:21
                            [post_date_gmt] => 2021-12-27 16:28:21
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 16:10:13
                            [post_modified_gmt] => 2022-12-14 16:10:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4041
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [392] => WP_Post Object
                        (
                            [ID] => 4040
                            [post_author] => 5
                            [post_date] => 2021-12-27 15:24:04
                            [post_date_gmt] => 2021-12-27 15:24:04
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 15:43:52
                            [post_modified_gmt] => 2022-12-14 15:43:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4040
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [393] => WP_Post Object
                        (
                            [ID] => 4038
                            [post_author] => 5
                            [post_date] => 2021-12-27 15:08:30
                            [post_date_gmt] => 2021-12-27 15:08:30
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-24 12:22:28
                            [post_modified_gmt] => 2022-01-24 12:22:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4038
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [394] => WP_Post Object
                        (
                            [ID] => 4036
                            [post_author] => 5
                            [post_date] => 2021-12-26 17:01:45
                            [post_date_gmt] => 2021-12-26 17:01:45
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-27 09:46:09
                            [post_modified_gmt] => 2022-09-27 09:46:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4036
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [395] => WP_Post Object
                        (
                            [ID] => 4035
                            [post_author] => 5
                            [post_date] => 2021-12-26 16:47:36
                            [post_date_gmt] => 2021-12-26 16:47:36
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 13:28:18
                            [post_modified_gmt] => 2022-12-16 13:28:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4035
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [396] => WP_Post Object
                        (
                            [ID] => 4032
                            [post_author] => 5
                            [post_date] => 2021-12-26 16:32:27
                            [post_date_gmt] => 2021-12-26 16:32:27
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 12:43:01
                            [post_modified_gmt] => 2022-12-16 12:43:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4032
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [397] => WP_Post Object
                        (
                            [ID] => 4029
                            [post_author] => 5
                            [post_date] => 2021-12-21 12:22:08
                            [post_date_gmt] => 2021-12-21 12:22:08
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 13:19:58
                            [post_modified_gmt] => 2022-10-13 13:19:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4029
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [398] => WP_Post Object
                        (
                            [ID] => 4028
                            [post_author] => 5
                            [post_date] => 2021-12-21 11:55:28
                            [post_date_gmt] => 2021-12-21 11:55:28
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 11:03:21
                            [post_modified_gmt] => 2022-07-13 11:03:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4028
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [399] => WP_Post Object
                        (
                            [ID] => 4024
                            [post_author] => 5
                            [post_date] => 2021-12-15 15:33:17
                            [post_date_gmt] => 2021-12-15 15:33:17
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-12-15 15:33:17
                            [post_modified_gmt] => 2021-12-15 15:33:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4024
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [400] => WP_Post Object
                        (
                            [ID] => 4022
                            [post_author] => 5
                            [post_date] => 2021-12-15 14:49:36
                            [post_date_gmt] => 2021-12-15 14:49:36
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-12-15 14:51:23
                            [post_modified_gmt] => 2021-12-15 14:51:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4022
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [401] => WP_Post Object
                        (
                            [ID] => 4021
                            [post_author] => 5
                            [post_date] => 2021-12-15 14:31:00
                            [post_date_gmt] => 2021-12-15 14:31:00
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 16:08:13
                            [post_modified_gmt] => 2023-01-04 16:08:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4021
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [402] => WP_Post Object
                        (
                            [ID] => 4020
                            [post_author] => 5
                            [post_date] => 2021-12-15 14:24:47
                            [post_date_gmt] => 2021-12-15 14:24:47
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:13:47
                            [post_modified_gmt] => 2023-01-04 15:13:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4020
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [403] => WP_Post Object
                        (
                            [ID] => 4017
                            [post_author] => 5
                            [post_date] => 2021-12-15 13:22:49
                            [post_date_gmt] => 2021-12-15 13:22:49
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-12-15 13:22:49
                            [post_modified_gmt] => 2021-12-15 13:22:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4017
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [404] => WP_Post Object
                        (
                            [ID] => 4016
                            [post_author] => 5
                            [post_date] => 2021-12-15 13:20:07
                            [post_date_gmt] => 2021-12-15 13:20:07
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 10:54:29
                            [post_modified_gmt] => 2022-09-29 10:54:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4016
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [405] => WP_Post Object
                        (
                            [ID] => 4014
                            [post_author] => 5
                            [post_date] => 2021-12-15 12:33:09
                            [post_date_gmt] => 2021-12-15 12:33:09
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 13:32:04
                            [post_modified_gmt] => 2022-12-16 13:32:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4014
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [406] => WP_Post Object
                        (
                            [ID] => 4013
                            [post_author] => 5
                            [post_date] => 2021-12-15 12:16:20
                            [post_date_gmt] => 2021-12-15 12:16:20
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:05:50
                            [post_modified_gmt] => 2022-10-12 13:05:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4013
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [407] => WP_Post Object
                        (
                            [ID] => 4011
                            [post_author] => 5
                            [post_date] => 2021-12-14 15:21:54
                            [post_date_gmt] => 2021-12-14 15:21:54
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 09:25:12
                            [post_modified_gmt] => 2022-07-13 09:25:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4011
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [408] => WP_Post Object
                        (
                            [ID] => 4009
                            [post_author] => 5
                            [post_date] => 2021-12-14 15:10:51
                            [post_date_gmt] => 2021-12-14 15:10:51
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-and-gsk-collaboration-and-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:21:09
                            [post_modified_gmt] => 2022-10-12 11:21:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4009
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [409] => WP_Post Object
                        (
                            [ID] => 4007
                            [post_author] => 5
                            [post_date] => 2021-12-14 08:51:32
                            [post_date_gmt] => 2021-12-14 08:51:32
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-12-14 08:51:44
                            [post_modified_gmt] => 2021-12-14 08:51:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4007
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [410] => WP_Post Object
                        (
                            [ID] => 4006
                            [post_author] => 5
                            [post_date] => 2021-12-14 08:16:01
                            [post_date_gmt] => 2021-12-14 08:16:01
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-19 15:38:00
                            [post_modified_gmt] => 2022-12-19 15:38:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4006
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [411] => WP_Post Object
                        (
                            [ID] => 4004
                            [post_author] => 5
                            [post_date] => 2021-12-14 07:57:41
                            [post_date_gmt] => 2021-12-14 07:57:41
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 15:44:19
                            [post_modified_gmt] => 2022-12-14 15:44:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4004
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [412] => WP_Post Object
                        (
                            [ID] => 4003
                            [post_author] => 5
                            [post_date] => 2021-12-13 18:36:53
                            [post_date_gmt] => 2021-12-13 18:36:53
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 14:03:19
                            [post_modified_gmt] => 2022-12-14 14:03:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4003
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [413] => WP_Post Object
                        (
                            [ID] => 4002
                            [post_author] => 5
                            [post_date] => 2021-12-13 18:28:05
                            [post_date_gmt] => 2021-12-13 18:28:05
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 14:57:35
                            [post_modified_gmt] => 2022-12-15 14:57:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4002
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [414] => WP_Post Object
                        (
                            [ID] => 3997
                            [post_author] => 5
                            [post_date] => 2021-12-13 14:24:49
                            [post_date_gmt] => 2021-12-13 14:24:49
                            [post_content] => 
                            [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 12:52:42
                            [post_modified_gmt] => 2022-07-13 12:52:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3997
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [415] => WP_Post Object
                        (
                            [ID] => 3914
                            [post_author] => 5
                            [post_date] => 2021-11-30 12:34:32
                            [post_date_gmt] => 2021-11-30 12:34:32
                            [post_content] => 
                            [post_title] => MPP – BMS Sublicense & Tech Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-bms-sublicense-tech-transfer-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 14:59:20
                            [post_modified_gmt] => 2022-12-15 14:59:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3914
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [416] => WP_Post Object
                        (
                            [ID] => 3909
                            [post_author] => 5
                            [post_date] => 2021-11-22 13:29:28
                            [post_date_gmt] => 2021-11-22 13:29:28
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:48:06
                            [post_modified_gmt] => 2023-01-27 14:48:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3909
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [417] => WP_Post Object
                        (
                            [ID] => 3908
                            [post_author] => 5
                            [post_date] => 2021-11-22 13:20:09
                            [post_date_gmt] => 2021-11-22 13:20:09
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:48:24
                            [post_modified_gmt] => 2023-01-27 14:48:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3908
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [418] => WP_Post Object
                        (
                            [ID] => 3907
                            [post_author] => 5
                            [post_date] => 2021-11-22 13:07:49
                            [post_date_gmt] => 2021-11-22 13:07:49
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:48:44
                            [post_modified_gmt] => 2023-01-27 14:48:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3907
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [419] => WP_Post Object
                        (
                            [ID] => 3906
                            [post_author] => 5
                            [post_date] => 2021-11-22 12:57:50
                            [post_date_gmt] => 2021-11-22 12:57:50
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:49:01
                            [post_modified_gmt] => 2023-01-27 14:49:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3906
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [420] => WP_Post Object
                        (
                            [ID] => 3904
                            [post_author] => 5
                            [post_date] => 2021-11-22 12:20:20
                            [post_date_gmt] => 2021-11-22 12:20:20
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:47:28
                            [post_modified_gmt] => 2023-01-27 14:47:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3904
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [421] => WP_Post Object
                        (
                            [ID] => 3903
                            [post_author] => 5
                            [post_date] => 2021-11-22 12:04:07
                            [post_date_gmt] => 2021-11-22 12:04:07
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:49:54
                            [post_modified_gmt] => 2023-01-27 14:49:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3903
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [422] => WP_Post Object
                        (
                            [ID] => 3901
                            [post_author] => 5
                            [post_date] => 2021-11-22 11:42:55
                            [post_date_gmt] => 2021-11-22 11:42:55
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:50:40
                            [post_modified_gmt] => 2023-01-27 14:50:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3901
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [423] => WP_Post Object
                        (
                            [ID] => 3900
                            [post_author] => 5
                            [post_date] => 2021-11-22 11:35:10
                            [post_date_gmt] => 2021-11-22 11:35:10
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:51:19
                            [post_modified_gmt] => 2023-01-27 14:51:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3900
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [424] => WP_Post Object
                        (
                            [ID] => 3899
                            [post_author] => 5
                            [post_date] => 2021-11-22 11:24:36
                            [post_date_gmt] => 2021-11-22 11:24:36
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:51:45
                            [post_modified_gmt] => 2023-01-27 14:51:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3899
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [425] => WP_Post Object
                        (
                            [ID] => 3898
                            [post_author] => 5
                            [post_date] => 2021-11-22 11:02:44
                            [post_date_gmt] => 2021-11-22 11:02:44
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:52:13
                            [post_modified_gmt] => 2023-01-27 14:52:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3898
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [426] => WP_Post Object
                        (
                            [ID] => 3897
                            [post_author] => 5
                            [post_date] => 2021-11-22 10:34:34
                            [post_date_gmt] => 2021-11-22 10:34:34
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:52:36
                            [post_modified_gmt] => 2023-01-27 14:52:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3897
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [427] => WP_Post Object
                        (
                            [ID] => 3896
                            [post_author] => 5
                            [post_date] => 2021-11-22 10:27:28
                            [post_date_gmt] => 2021-11-22 10:27:28
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:52:57
                            [post_modified_gmt] => 2023-01-27 14:52:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3896
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [428] => WP_Post Object
                        (
                            [ID] => 3895
                            [post_author] => 5
                            [post_date] => 2021-11-22 10:20:20
                            [post_date_gmt] => 2021-11-22 10:20:20
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:53:20
                            [post_modified_gmt] => 2023-01-27 14:53:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3895
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [429] => WP_Post Object
                        (
                            [ID] => 3892
                            [post_author] => 5
                            [post_date] => 2021-11-19 13:53:26
                            [post_date_gmt] => 2021-11-19 13:53:26
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:53:42
                            [post_modified_gmt] => 2023-01-27 14:53:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3892
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [430] => WP_Post Object
                        (
                            [ID] => 3891
                            [post_author] => 5
                            [post_date] => 2021-11-19 13:11:12
                            [post_date_gmt] => 2021-11-19 13:11:12
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:54:03
                            [post_modified_gmt] => 2023-01-27 14:54:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3891
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [431] => WP_Post Object
                        (
                            [ID] => 3869
                            [post_author] => 5
                            [post_date] => 2021-11-19 12:55:06
                            [post_date_gmt] => 2021-11-19 12:55:06
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-09 14:56:17
                            [post_modified_gmt] => 2022-11-09 14:56:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3869
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [432] => WP_Post Object
                        (
                            [ID] => 3886
                            [post_author] => 5
                            [post_date] => 2021-11-18 16:36:37
                            [post_date_gmt] => 2021-11-18 16:36:37
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:00:13
                            [post_modified_gmt] => 2022-12-15 15:00:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3886
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [433] => WP_Post Object
                        (
                            [ID] => 3884
                            [post_author] => 5
                            [post_date] => 2021-11-18 16:17:51
                            [post_date_gmt] => 2021-11-18 16:17:51
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:23:21
                            [post_modified_gmt] => 2022-10-12 11:23:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3884
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [434] => WP_Post Object
                        (
                            [ID] => 3883
                            [post_author] => 5
                            [post_date] => 2021-11-18 16:10:24
                            [post_date_gmt] => 2021-11-18 16:10:24
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 12:53:31
                            [post_modified_gmt] => 2023-01-03 12:53:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3883
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [435] => WP_Post Object
                        (
                            [ID] => 3882
                            [post_author] => 5
                            [post_date] => 2021-11-18 16:01:06
                            [post_date_gmt] => 2021-11-18 16:01:06
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 16:11:41
                            [post_modified_gmt] => 2023-01-04 16:11:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3882
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [436] => WP_Post Object
                        (
                            [ID] => 3881
                            [post_author] => 5
                            [post_date] => 2021-11-18 15:52:45
                            [post_date_gmt] => 2021-11-18 15:52:45
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:15:40
                            [post_modified_gmt] => 2023-01-04 15:15:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3881
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [437] => WP_Post Object
                        (
                            [ID] => 3880
                            [post_author] => 5
                            [post_date] => 2021-11-18 15:50:26
                            [post_date_gmt] => 2021-11-18 15:50:26
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-18 15:50:26
                            [post_modified_gmt] => 2021-11-18 15:50:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3880
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [438] => WP_Post Object
                        (
                            [ID] => 3878
                            [post_author] => 5
                            [post_date] => 2021-11-18 15:08:19
                            [post_date_gmt] => 2021-11-18 15:08:19
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-18 15:08:19
                            [post_modified_gmt] => 2021-11-18 15:08:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3878
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [439] => WP_Post Object
                        (
                            [ID] => 3877
                            [post_author] => 5
                            [post_date] => 2021-11-18 15:05:16
                            [post_date_gmt] => 2021-11-18 15:05:16
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:45:57
                            [post_modified_gmt] => 2022-09-29 11:45:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3877
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [440] => WP_Post Object
                        (
                            [ID] => 3876
                            [post_author] => 5
                            [post_date] => 2021-11-18 14:51:40
                            [post_date_gmt] => 2021-11-18 14:51:40
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 15:45:13
                            [post_modified_gmt] => 2022-12-14 15:45:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3876
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [441] => WP_Post Object
                        (
                            [ID] => 3875
                            [post_author] => 5
                            [post_date] => 2021-11-18 14:43:39
                            [post_date_gmt] => 2021-11-18 14:43:39
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-22 10:50:23
                            [post_modified_gmt] => 2021-11-22 10:50:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3875
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [442] => WP_Post Object
                        (
                            [ID] => 3874
                            [post_author] => 5
                            [post_date] => 2021-11-18 14:29:06
                            [post_date_gmt] => 2021-11-18 14:29:06
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-19 15:40:42
                            [post_modified_gmt] => 2022-12-19 15:40:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3874
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [443] => WP_Post Object
                        (
                            [ID] => 3873
                            [post_author] => 5
                            [post_date] => 2021-11-18 14:05:12
                            [post_date_gmt] => 2021-11-18 14:05:12
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 12:45:08
                            [post_modified_gmt] => 2022-12-16 12:45:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3873
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [444] => WP_Post Object
                        (
                            [ID] => 3870
                            [post_author] => 5
                            [post_date] => 2021-11-18 12:58:35
                            [post_date_gmt] => 2021-11-18 12:58:35
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 13:14:06
                            [post_modified_gmt] => 2022-07-13 13:14:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3870
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [445] => WP_Post Object
                        (
                            [ID] => 3863
                            [post_author] => 5
                            [post_date] => 2021-11-05 14:19:38
                            [post_date_gmt] => 2021-11-05 14:19:38
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:00:47
                            [post_modified_gmt] => 2022-12-15 15:00:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3863
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [446] => WP_Post Object
                        (
                            [ID] => 3861
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:59:54
                            [post_date_gmt] => 2021-11-05 13:59:54
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:24:33
                            [post_modified_gmt] => 2022-10-12 11:24:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3861
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [447] => WP_Post Object
                        (
                            [ID] => 3860
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:51:48
                            [post_date_gmt] => 2021-11-05 13:51:48
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 07:16:48
                            [post_modified_gmt] => 2022-04-18 07:16:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3860
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [448] => WP_Post Object
                        (
                            [ID] => 3859
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:44:47
                            [post_date_gmt] => 2021-11-05 13:44:47
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 16:12:49
                            [post_modified_gmt] => 2023-01-04 16:12:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3859
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [449] => WP_Post Object
                        (
                            [ID] => 3858
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:39:37
                            [post_date_gmt] => 2021-11-05 13:39:37
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:16:05
                            [post_modified_gmt] => 2023-01-04 15:16:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3858
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [450] => WP_Post Object
                        (
                            [ID] => 3857
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:37:12
                            [post_date_gmt] => 2021-11-05 13:37:12
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 07:41:41
                            [post_modified_gmt] => 2022-04-18 07:41:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3857
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [451] => WP_Post Object
                        (
                            [ID] => 3856
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:12:38
                            [post_date_gmt] => 2021-11-05 13:12:38
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:54:20
                            [post_modified_gmt] => 2022-09-26 14:54:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3856
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [452] => WP_Post Object
                        (
                            [ID] => 3855
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:10:25
                            [post_date_gmt] => 2021-11-05 13:10:25
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-06 10:08:38
                            [post_modified_gmt] => 2022-07-06 10:08:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3855
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [453] => WP_Post Object
                        (
                            [ID] => 3854
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:03:41
                            [post_date_gmt] => 2021-11-05 13:03:41
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 08:15:00
                            [post_modified_gmt] => 2022-04-18 08:15:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3854
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [454] => WP_Post Object
                        (
                            [ID] => 3852
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:43:57
                            [post_date_gmt] => 2021-11-05 12:43:57
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 08:33:20
                            [post_modified_gmt] => 2022-04-18 08:33:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3852
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [455] => WP_Post Object
                        (
                            [ID] => 3851
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:41:54
                            [post_date_gmt] => 2021-11-05 12:41:54
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:14:19
                            [post_modified_gmt] => 2022-10-12 13:14:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3851
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [456] => WP_Post Object
                        (
                            [ID] => 3849
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:30:09
                            [post_date_gmt] => 2021-11-05 12:30:09
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 08:52:12
                            [post_modified_gmt] => 2022-04-18 08:52:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3849
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [457] => WP_Post Object
                        (
                            [ID] => 3848
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:27:44
                            [post_date_gmt] => 2021-11-05 12:27:44
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:36:29
                            [post_modified_gmt] => 2022-12-15 16:36:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3848
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [458] => WP_Post Object
                        (
                            [ID] => 3847
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:25:40
                            [post_date_gmt] => 2021-11-05 12:25:40
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-09 14:58:58
                            [post_modified_gmt] => 2022-11-09 14:58:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3847
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [459] => WP_Post Object
                        (
                            [ID] => 3846
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:14:17
                            [post_date_gmt] => 2021-11-05 12:14:17
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 13:02:17
                            [post_modified_gmt] => 2022-07-13 13:02:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3846
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [460] => WP_Post Object
                        (
                            [ID] => 3819
                            [post_author] => 6
                            [post_date] => 2021-09-15 12:17:55
                            [post_date_gmt] => 2021-09-15 12:17:55
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-and-gsk-collaboration-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-09 14:59:50
                            [post_modified_gmt] => 2022-11-09 14:59:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3819
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [461] => WP_Post Object
                        (
                            [ID] => 3812
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:44:57
                            [post_date_gmt] => 2021-09-10 12:44:57
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:53:37
                            [post_modified_gmt] => 2022-10-03 13:53:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3812
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [462] => WP_Post Object
                        (
                            [ID] => 3810
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:21:33
                            [post_date_gmt] => 2021-09-10 12:21:33
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:25:05
                            [post_modified_gmt] => 2022-10-12 11:25:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3810
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [463] => WP_Post Object
                        (
                            [ID] => 3809
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:11:12
                            [post_date_gmt] => 2021-09-10 12:11:12
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:54:22
                            [post_modified_gmt] => 2022-10-03 13:54:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3809
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [464] => WP_Post Object
                        (
                            [ID] => 3808
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:59:11
                            [post_date_gmt] => 2021-09-10 11:59:11
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 08:32:00
                            [post_modified_gmt] => 2022-12-16 08:32:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3808
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [465] => WP_Post Object
                        (
                            [ID] => 3807
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:55:25
                            [post_date_gmt] => 2021-09-10 11:55:25
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:01:53
                            [post_modified_gmt] => 2022-12-15 15:01:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3807
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [466] => WP_Post Object
                        (
                            [ID] => 3806
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:47:18
                            [post_date_gmt] => 2021-09-10 11:47:18
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:55:26
                            [post_modified_gmt] => 2022-10-03 13:55:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3806
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [467] => WP_Post Object
                        (
                            [ID] => 3805
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:33:53
                            [post_date_gmt] => 2021-09-10 11:33:53
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 13:02:35
                            [post_modified_gmt] => 2023-01-03 13:02:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3805
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [468] => WP_Post Object
                        (
                            [ID] => 3804
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:20:59
                            [post_date_gmt] => 2021-09-10 11:20:59
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:17:01
                            [post_modified_gmt] => 2023-01-04 15:17:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3804
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [469] => WP_Post Object
                        (
                            [ID] => 3803
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:54:42
                            [post_date_gmt] => 2021-09-10 10:54:42
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:57:32
                            [post_modified_gmt] => 2022-10-03 13:57:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3803
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [470] => WP_Post Object
                        (
                            [ID] => 3802
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:45:57
                            [post_date_gmt] => 2021-09-10 10:45:57
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:58:08
                            [post_modified_gmt] => 2022-10-03 13:58:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3802
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [471] => WP_Post Object
                        (
                            [ID] => 3801
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:36:30
                            [post_date_gmt] => 2021-09-10 10:36:30
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 15:47:05
                            [post_modified_gmt] => 2022-12-14 15:47:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3801
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [472] => WP_Post Object
                        (
                            [ID] => 3800
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:25:59
                            [post_date_gmt] => 2021-09-10 10:25:59
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:58:45
                            [post_modified_gmt] => 2022-10-03 13:58:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3800
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [473] => WP_Post Object
                        (
                            [ID] => 3799
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:07:18
                            [post_date_gmt] => 2021-09-10 10:07:18
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 12:45:40
                            [post_modified_gmt] => 2022-12-16 12:45:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3799
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [474] => WP_Post Object
                        (
                            [ID] => 3798
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:02:07
                            [post_date_gmt] => 2021-09-10 10:02:07
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:59:19
                            [post_modified_gmt] => 2022-10-03 13:59:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3798
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [475] => WP_Post Object
                        (
                            [ID] => 3797
                            [post_author] => 5
                            [post_date] => 2021-09-10 09:54:44
                            [post_date_gmt] => 2021-09-10 09:54:44
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-03 13:59:36
                            [post_modified_gmt] => 2022-10-03 13:59:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3797
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [476] => WP_Post Object
                        (
                            [ID] => 3796
                            [post_author] => 5
                            [post_date] => 2021-09-10 09:03:43
                            [post_date_gmt] => 2021-09-10 09:03:43
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-09 15:00:19
                            [post_modified_gmt] => 2022-11-09 15:00:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3796
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [477] => WP_Post Object
                        (
                            [ID] => 3792
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:23:13
                            [post_date_gmt] => 2021-09-09 14:23:13
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:24:00
                            [post_modified_gmt] => 2022-12-14 13:24:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3792
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [478] => WP_Post Object
                        (
                            [ID] => 3791
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:18:44
                            [post_date_gmt] => 2021-09-09 14:18:44
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 13:14:39
                            [post_modified_gmt] => 2023-01-03 13:14:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3791
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [479] => WP_Post Object
                        (
                            [ID] => 3789
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:07:30
                            [post_date_gmt] => 2021-09-09 14:07:30
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:32:36
                            [post_modified_gmt] => 2022-09-29 12:32:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3789
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [480] => WP_Post Object
                        (
                            [ID] => 3788
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:00:40
                            [post_date_gmt] => 2021-09-09 14:00:40
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-04 09:02:12
                            [post_modified_gmt] => 2021-11-04 09:02:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3788
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [481] => WP_Post Object
                        (
                            [ID] => 3786
                            [post_author] => 5
                            [post_date] => 2021-09-09 13:20:21
                            [post_date_gmt] => 2021-09-09 13:20:21
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 08:10:12
                            [post_modified_gmt] => 2022-12-15 08:10:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3786
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [482] => WP_Post Object
                        (
                            [ID] => 3784
                            [post_author] => 5
                            [post_date] => 2021-09-09 13:03:52
                            [post_date_gmt] => 2021-09-09 13:03:52
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 12:52:03
                            [post_modified_gmt] => 2022-12-16 12:52:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3784
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [483] => WP_Post Object
                        (
                            [ID] => 3783
                            [post_author] => 5
                            [post_date] => 2021-09-09 12:41:47
                            [post_date_gmt] => 2021-09-09 12:41:47
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 13:33:19
                            [post_modified_gmt] => 2022-12-16 13:33:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3783
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [484] => WP_Post Object
                        (
                            [ID] => 3782
                            [post_author] => 5
                            [post_date] => 2021-09-09 12:36:36
                            [post_date_gmt] => 2021-09-09 12:36:36
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:05:58
                            [post_modified_gmt] => 2022-12-15 15:05:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3782
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [485] => WP_Post Object
                        (
                            [ID] => 3781
                            [post_author] => 5
                            [post_date] => 2021-09-09 12:29:54
                            [post_date_gmt] => 2021-09-09 12:29:54
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:06:09
                            [post_modified_gmt] => 2022-12-15 15:06:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3781
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [486] => WP_Post Object
                        (
                            [ID] => 3778
                            [post_author] => 5
                            [post_date] => 2021-09-09 11:52:53
                            [post_date_gmt] => 2021-09-09 11:52:53
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-10 12:13:07
                            [post_modified_gmt] => 2022-11-10 12:13:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3778
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [487] => WP_Post Object
                        (
                            [ID] => 3765
                            [post_author] => 5
                            [post_date] => 2021-09-01 14:09:03
                            [post_date_gmt] => 2021-09-01 14:09:03
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 08:33:18
                            [post_modified_gmt] => 2022-12-16 08:33:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3765
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [488] => WP_Post Object
                        (
                            [ID] => 3764
                            [post_author] => 5
                            [post_date] => 2021-09-01 12:17:32
                            [post_date_gmt] => 2021-09-01 12:17:32
                            [post_content] => 
                            [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => barda-moderna-covid-19-vaccine-development-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:59:16
                            [post_modified_gmt] => 2022-09-26 14:59:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3764
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [489] => WP_Post Object
                        (
                            [ID] => 3758
                            [post_author] => 5
                            [post_date] => 2021-08-26 12:04:03
                            [post_date_gmt] => 2021-08-26 12:04:03
                            [post_content] => 
                            [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => barda-moderna-covid-19-vaccine-development-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 08:34:19
                            [post_modified_gmt] => 2022-12-16 08:34:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3758
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [490] => WP_Post Object
                        (
                            [ID] => 3757
                            [post_author] => 5
                            [post_date] => 2021-08-25 08:42:34
                            [post_date_gmt] => 2021-08-25 08:42:34
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-18
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-11 15:47:08
                            [post_modified_gmt] => 2023-01-11 15:47:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3757
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [491] => WP_Post Object
                        (
                            [ID] => 3756
                            [post_author] => 5
                            [post_date] => 2021-08-25 08:10:37
                            [post_date_gmt] => 2021-08-25 08:10:37
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-11 15:39:31
                            [post_modified_gmt] => 2023-01-11 15:39:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3756
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [492] => WP_Post Object
                        (
                            [ID] => 3755
                            [post_author] => 5
                            [post_date] => 2021-08-25 07:55:51
                            [post_date_gmt] => 2021-08-25 07:55:51
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-19 09:24:11
                            [post_modified_gmt] => 2023-01-19 09:24:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3755
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [493] => WP_Post Object
                        (
                            [ID] => 3754
                            [post_author] => 5
                            [post_date] => 2021-08-24 13:43:37
                            [post_date_gmt] => 2021-08-24 13:43:37
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-12 13:59:38
                            [post_modified_gmt] => 2023-01-12 13:59:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3754
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [494] => WP_Post Object
                        (
                            [ID] => 3753
                            [post_author] => 5
                            [post_date] => 2021-08-24 13:14:41
                            [post_date_gmt] => 2021-08-24 13:14:41
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-19 10:13:40
                            [post_modified_gmt] => 2023-01-19 10:13:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3753
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [495] => WP_Post Object
                        (
                            [ID] => 3751
                            [post_author] => 5
                            [post_date] => 2021-08-24 12:54:56
                            [post_date_gmt] => 2021-08-24 12:54:56
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-12 13:20:29
                            [post_modified_gmt] => 2023-01-12 13:20:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3751
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [496] => WP_Post Object
                        (
                            [ID] => 3749
                            [post_author] => 5
                            [post_date] => 2021-08-24 12:40:53
                            [post_date_gmt] => 2021-08-24 12:40:53
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-12 13:33:44
                            [post_modified_gmt] => 2023-01-12 13:33:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3749
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [497] => WP_Post Object
                        (
                            [ID] => 3748
                            [post_author] => 5
                            [post_date] => 2021-08-24 12:31:07
                            [post_date_gmt] => 2021-08-24 12:31:07
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-11 14:17:38
                            [post_modified_gmt] => 2023-01-11 14:17:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3748
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [498] => WP_Post Object
                        (
                            [ID] => 3747
                            [post_author] => 5
                            [post_date] => 2021-08-24 11:12:07
                            [post_date_gmt] => 2021-08-24 11:12:07
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-11 15:28:33
                            [post_modified_gmt] => 2023-01-11 15:28:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3747
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [499] => WP_Post Object
                        (
                            [ID] => 3746
                            [post_author] => 5
                            [post_date] => 2021-08-24 10:45:05
                            [post_date_gmt] => 2021-08-24 10:45:05
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-11 15:55:51
                            [post_modified_gmt] => 2023-01-11 15:55:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3746
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [500] => WP_Post Object
                        (
                            [ID] => 3744
                            [post_author] => 5
                            [post_date] => 2021-08-24 10:32:54
                            [post_date_gmt] => 2021-08-24 10:32:54
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-11 15:52:06
                            [post_modified_gmt] => 2023-01-11 15:52:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3744
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [501] => WP_Post Object
                        (
                            [ID] => 3743
                            [post_author] => 5
                            [post_date] => 2021-08-24 10:19:00
                            [post_date_gmt] => 2021-08-24 10:19:00
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-11 15:53:13
                            [post_modified_gmt] => 2023-01-11 15:53:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3743
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [502] => WP_Post Object
                        (
                            [ID] => 3741
                            [post_author] => 5
                            [post_date] => 2021-08-24 09:13:39
                            [post_date_gmt] => 2021-08-24 09:13:39
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:25:32
                            [post_modified_gmt] => 2022-09-26 14:25:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3741
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [503] => WP_Post Object
                        (
                            [ID] => 3736
                            [post_author] => 5
                            [post_date] => 2021-08-24 07:47:09
                            [post_date_gmt] => 2021-08-24 07:47:09
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-13 14:46:43
                            [post_modified_gmt] => 2023-01-13 14:46:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3736
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [504] => WP_Post Object
                        (
                            [ID] => 3726
                            [post_author] => 5
                            [post_date] => 2021-08-23 16:13:39
                            [post_date_gmt] => 2021-08-23 16:13:39
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-11 15:23:48
                            [post_modified_gmt] => 2023-01-11 15:23:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3726
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [505] => WP_Post Object
                        (
                            [ID] => 3725
                            [post_author] => 5
                            [post_date] => 2021-08-23 13:56:41
                            [post_date_gmt] => 2021-08-23 13:56:41
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-11 15:50:35
                            [post_modified_gmt] => 2023-01-11 15:50:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3725
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [506] => WP_Post Object
                        (
                            [ID] => 3724
                            [post_author] => 5
                            [post_date] => 2021-08-23 13:11:07
                            [post_date_gmt] => 2021-08-23 13:11:07
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-11 15:27:12
                            [post_modified_gmt] => 2023-01-11 15:27:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3724
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [507] => WP_Post Object
                        (
                            [ID] => 3722
                            [post_author] => 5
                            [post_date] => 2021-08-23 12:12:50
                            [post_date_gmt] => 2021-08-23 12:12:50
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-11 15:42:28
                            [post_modified_gmt] => 2023-01-11 15:42:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3722
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [508] => WP_Post Object
                        (
                            [ID] => 3698
                            [post_author] => 5
                            [post_date] => 2021-08-19 14:33:22
                            [post_date_gmt] => 2021-08-19 14:33:22
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-model-inter-institutional-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 15:47:55
                            [post_modified_gmt] => 2022-12-14 15:47:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3698
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [509] => WP_Post Object
                        (
                            [ID] => 3696
                            [post_author] => 5
                            [post_date] => 2021-08-19 14:23:22
                            [post_date_gmt] => 2021-08-19 14:23:22
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 07:52:58
                            [post_modified_gmt] => 2022-12-15 07:52:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3696
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [510] => WP_Post Object
                        (
                            [ID] => 3694
                            [post_author] => 5
                            [post_date] => 2021-08-18 09:56:18
                            [post_date_gmt] => 2021-08-18 09:56:18
                            [post_content] => 
                            [post_title] => Gilead - Indian Generic Manufacturers, HCV License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-indian-generic-manufacturers-hcv-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-19 15:42:35
                            [post_modified_gmt] => 2022-12-19 15:42:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3694
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [511] => WP_Post Object
                        (
                            [ID] => 3691
                            [post_author] => 5
                            [post_date] => 2021-08-18 09:29:08
                            [post_date_gmt] => 2021-08-18 09:29:08
                            [post_content] => 
                            [post_title] => Gilead - Indian Generic Manufacturers, HCV License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-indian-generic-manufacturers-hcv-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 15:48:43
                            [post_modified_gmt] => 2022-12-14 15:48:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3691
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [512] => WP_Post Object
                        (
                            [ID] => 3689
                            [post_author] => 5
                            [post_date] => 2021-08-18 09:13:21
                            [post_date_gmt] => 2021-08-18 09:13:21
                            [post_content] => 
                            [post_title] => Gilead - Indian Generic Manufacturers, HCV License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-indian-generic-manufacturers-hcv-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:30:10
                            [post_modified_gmt] => 2022-09-29 11:30:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3689
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [513] => WP_Post Object
                        (
                            [ID] => 3495
                            [post_author] => 5
                            [post_date] => 2021-08-10 13:06:45
                            [post_date_gmt] => 2021-08-10 13:06:45
                            [post_content] => 
                            [post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dod-moderna-covid-19-vaccine-supply-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 09:00:22
                            [post_modified_gmt] => 2022-12-15 09:00:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3495
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [514] => WP_Post Object
                        (
                            [ID] => 3493
                            [post_author] => 5
                            [post_date] => 2021-08-10 11:15:39
                            [post_date_gmt] => 2021-08-10 11:15:39
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-10 14:19:31
                            [post_modified_gmt] => 2023-01-10 14:19:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3493
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [515] => WP_Post Object
                        (
                            [ID] => 3436
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:48:49
                            [post_date_gmt] => 2021-07-01 03:48:49
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:25:22
                            [post_modified_gmt] => 2022-09-29 11:25:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3436
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [516] => WP_Post Object
                        (
                            [ID] => 3434
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:44:18
                            [post_date_gmt] => 2021-07-01 03:44:18
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:34:30
                            [post_modified_gmt] => 2022-10-12 13:34:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3434
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [517] => WP_Post Object
                        (
                            [ID] => 3433
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:41:21
                            [post_date_gmt] => 2021-07-01 03:41:21
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 14:50:06
                            [post_modified_gmt] => 2022-12-14 14:50:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3433
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [518] => WP_Post Object
                        (
                            [ID] => 3431
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:38:49
                            [post_date_gmt] => 2021-07-01 03:38:49
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 09:41:10
                            [post_modified_gmt] => 2022-04-18 09:41:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3431
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [519] => WP_Post Object
                        (
                            [ID] => 3430
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:27:51
                            [post_date_gmt] => 2021-07-01 03:27:51
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-04-18 09:45:31
                            [post_modified_gmt] => 2022-04-18 09:45:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3430
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [520] => WP_Post Object
                        (
                            [ID] => 3428
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:24:00
                            [post_date_gmt] => 2021-07-01 03:24:00
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-26 14:52:47
                            [post_modified_gmt] => 2022-09-26 14:52:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3428
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [521] => WP_Post Object
                        (
                            [ID] => 3427
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:22:23
                            [post_date_gmt] => 2021-07-01 03:22:23
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 11:35:43
                            [post_modified_gmt] => 2022-10-12 11:35:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3427
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [522] => WP_Post Object
                        (
                            [ID] => 3426
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:06:23
                            [post_date_gmt] => 2021-07-01 03:06:23
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:25:19
                            [post_modified_gmt] => 2023-01-04 15:25:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3426
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [523] => WP_Post Object
                        (
                            [ID] => 3424
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:03:57
                            [post_date_gmt] => 2021-07-01 03:03:57
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:14:06
                            [post_modified_gmt] => 2022-12-15 15:14:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3424
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [524] => WP_Post Object
                        (
                            [ID] => 3422
                            [post_author] => 6
                            [post_date] => 2021-07-01 02:58:21
                            [post_date_gmt] => 2021-07-01 02:58:21
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-10 12:14:53
                            [post_modified_gmt] => 2022-11-10 12:14:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3422
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [525] => WP_Post Object
                        (
                            [ID] => 3421
                            [post_author] => 6